<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Novartis - Wikipedia, the free encyclopedia</title>
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />
<meta name="generator" content="MediaWiki 1.23wmf20" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Novartis" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Novartis&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Novartis&amp;action=edit" />
<link rel="apple-touch-icon" href="//bits.wikimedia.org/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="//bits.wikimedia.org/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="http://en.wikipedia.org/wiki/Novartis" />
<link rel="stylesheet" href="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.ui.button%7Cskins.common.interface%7Cskins.vector.styles&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: enwiki:resourceloader:filter:minify-css:7:3904d24a08aa08f6a68dc338f9be277e */</style>

<script src="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Novartis","wgTitle":"Novartis","wgCurRevisionId":602624408,"wgRevisionId":602624408,"wgArticleId":159284,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["All articles with dead external links","Articles with dead external links from January 2011","Articles containing potentially dated statements from 2013","All articles containing potentially dated statements","Commons category with local link same as on Wikidata","Companies listed on the New York Stock Exchange","Biotechnology companies","Multinational companies headquartered in Switzerland","Novartis","Pharmaceutical companies of Switzerland","Vaccine producers","Veterinary medicine companies","Companies established in 1996","Companies based in Basel"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Novartis","wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"templateEditor":false,"templates":false,"preview":false,"previewDialog":false,"publish":false,"toc":false},"wgBetaFeaturesFeatures":[],"wgMediaViewerOnClick":false,"wgVisualEditor":{"isPageWatched":false,"magnifyClipIconURL":"//bits.wikimedia.org/static-1.23wmf20/skins/common/images/magnify-clip.png","pageLanguageCode":"en","pageLanguageDir":"ltr","svgMaxSize":2048},"wikilove-recipient":"","wikilove-anon":0,"wgGuidedTourHelpGuiderUrl":"Help:Guided tours/guider","wgFlowTermsOfUseEdit":"By saving changes, you agree to our \u003Ca class=\"external text\" href=\"//wikimediafoundation.org/wiki/Terms_of_use\"\u003ETerms of Use\u003C/a\u003E and agree to irrevocably release your text under the \u003Ca rel=\"nofollow\" class=\"external text\" href=\"//creativecommons.org/licenses/by-sa/3.0\"\u003ECC BY-SA 3.0 License\u003C/a\u003E and \u003Ca class=\"external text\" href=\"//en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License\"\u003EGFDL\u003C/a\u003E","wgULSAcceptLanguageList":["en-us","en"],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q507154"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function(){mw.user.options.set({"ccmeonemails":0,"cols":80,"date":"default","diffonly":0,"disablemail":0,"editfont":"default","editondblclick":0,"editsectiononrightclick":0,"enotifminoredits":0,"enotifrevealaddr":0,"enotifusertalkpages":1,"enotifwatchlistpages":0,"extendwatchlist":0,"fancysig":0,"forceeditsummary":0,"gender":"unknown","hideminor":0,"hidepatrolled":0,"imagesize":2,"math":0,"minordefault":0,"newpageshidepatrolled":0,"nickname":"","norollbackdiff":0,"numberheadings":0,"previewonfirst":0,"previewontop":1,"rcdays":7,"rclimit":50,"rememberpassword":0,"rows":25,"showhiddencats":false,"shownumberswatching":1,"showtoolbar":1,"skin":"vector","stubthreshold":0,"thumbsize":4,"underline":2,"uselivepreview":0,"usenewrc":0,"watchcreations":1,"watchdefault":0,"watchdeletion":0,"watchlistdays":3,"watchlisthideanons":0,"watchlisthidebots":0,"watchlisthideliu":0,"watchlisthideminor":0,"watchlisthideown":0,"watchlisthidepatrolled":0,"watchmoves":0,
"wllimit":250,"useeditwarning":1,"prefershttps":1,"flaggedrevssimpleui":1,"flaggedrevsstable":0,"flaggedrevseditdiffs":true,"flaggedrevsviewdiffs":false,"usebetatoolbar":1,"usebetatoolbar-cgd":1,"multimediaviewer-enable":true,"visualeditor-enable":0,"visualeditor-enable-experimental":0,"visualeditor-betatempdisable":0,"wikilove-enabled":1,"echo-subscriptions-web-page-review":true,"echo-subscriptions-email-page-review":false,"ep_showtoplink":false,"ep_bulkdelorgs":false,"ep_bulkdelcourses":true,"ep_showdyk":true,"echo-subscriptions-web-education-program":true,"echo-subscriptions-email-education-program":false,"echo-notify-show-link":true,"echo-show-alert":true,"echo-email-frequency":0,"echo-email-format":"html","echo-subscriptions-email-system":true,"echo-subscriptions-web-system":true,"echo-subscriptions-email-other":false,"echo-subscriptions-web-other":true,"echo-subscriptions-email-edit-user-talk":false,"echo-subscriptions-web-edit-user-talk":true,"echo-subscriptions-email-reverted":
false,"echo-subscriptions-web-reverted":true,"echo-subscriptions-email-article-linked":false,"echo-subscriptions-web-article-linked":false,"echo-subscriptions-email-mention":false,"echo-subscriptions-web-mention":true,"echo-subscriptions-web-edit-thank":true,"echo-subscriptions-email-edit-thank":false,"echo-subscriptions-web-flow-discussion":true,"echo-subscriptions-email-flow-discussion":false,"gettingstarted-task-toolbar-show-intro":true,"uls-preferences":"","language":"en","variant-gan":"gan","variant-iu":"iu","variant-kk":"kk","variant-ku":"ku","variant-shi":"shi","variant-sr":"sr","variant-tg":"tg","variant-uz":"uz","variant-zh":"zh","searchNs0":true,"searchNs1":false,"searchNs2":false,"searchNs3":false,"searchNs4":false,"searchNs5":false,"searchNs6":false,"searchNs7":false,"searchNs8":false,"searchNs9":false,"searchNs10":false,"searchNs11":false,"searchNs12":false,"searchNs13":false,"searchNs14":false,"searchNs15":false,"searchNs100":false,"searchNs101":false,"searchNs108":false,
"searchNs109":false,"searchNs118":false,"searchNs119":false,"searchNs446":false,"searchNs447":false,"searchNs710":false,"searchNs711":false,"searchNs828":false,"searchNs829":false,"gadget-teahouse":1,"gadget-ReferenceTooltips":1,"gadget-DRN-wizard":1,"gadget-charinsert":1,"gadget-mySandbox":1,"variant":"en"});},{},{});mw.loader.implement("user.tokens",function(){mw.user.tokens.set({"editToken":"+\\","patrolToken":false,"watchToken":false});},{},{});
/* cache key: enwiki:resourceloader:filter:minify-js:7:f91b7921db835befbf3c85fee027f8c0 */
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","skins.vector.compactPersonalBar.defaultTracking","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","wikibase.client.init","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" /><!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static-1.23wmf20/skins/vector/csshover.min.htc")}</style><![endif]--></head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Novartis skin-vector action-view vector-animateLayout">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>
			<div id="mw-js-message" style="display:none;"></div>
						<div id="siteNotice"><!-- CentralNotice --></div>
						<h1 id="firstHeading" class="firstHeading" lang="en"><span dir="auto">Novartis</span></h1>
						<div id="bodyContent">
								<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-navigation">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="dablink">"Sandoz" redirects here. For other uses, see <a href="/wiki/Sandoz_(disambiguation)" title="Sandoz (disambiguation)">Sandoz (disambiguation)</a>.</div>
<table class="infobox vcard" cellspacing="3" style="border-spacing:3px;width:22em;">
<caption class="fn org">Novartis International AG</caption>
<tr>
<td colspan="2" class="logo" style="text-align:center;"><a href="/wiki/File:Novartis.svg" class="image"><img alt="Novartis.svg" src="//upload.wikimedia.org/wikipedia/en/thumb/7/76/Novartis.svg/220px-Novartis.svg.png" width="220" height="39" srcset="//upload.wikimedia.org/wikipedia/en/thumb/7/76/Novartis.svg/330px-Novartis.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/7/76/Novartis.svg/440px-Novartis.svg.png 2x" /></a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Types_of_business_entity" title="Types of business entity">Type</a></th>
<td class="category"><a href="/wiki/Public_company" title="Public company">Public</a> <a href="/wiki/Aktiengesellschaft" title="Aktiengesellschaft">AG</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Ticker_symbol" title="Ticker symbol">Traded as</a></th>
<td><a href="/wiki/SIX_Swiss_Exchange" title="SIX Swiss Exchange">SIX</a>:&#160;<a rel="nofollow" class="external text" href="http://www.six-swiss-exchange.com/search/quotes_en.html?security=NOVN">NOVN</a>, <a href="/wiki/New_York_Stock_Exchange" title="New York Stock Exchange">NYSE</a>:&#160;<a rel="nofollow" class="external text" href="http://www.nyse.com/about/listed/quickquote.html?ticker=nvs">NVS</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;">Industry</th>
<td class="category"><a href="/wiki/Pharmaceutical_industry" title="Pharmaceutical industry">Pharmaceuticals</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;">Founded</th>
<td>1996 (from merger)</td>
</tr>
<tr>
<th scope="row" style="text-align:left;">Headquarters</th>
<td class="label"><a href="/wiki/Basel" title="Basel">Basel</a>, Basel-Stadt, <a href="/wiki/Switzerland" title="Switzerland">Switzerland</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;">Key people</th>
<td class="agent"><a href="/w/index.php?title=Joerg_Reinhardt&amp;action=edit&amp;redlink=1" class="new" title="Joerg Reinhardt (page does not exist)">Joerg Reinhardt</a> <small>(<a href="/wiki/Chairman" title="Chairman">Chairman</a>)</small>, <a href="/wiki/Joseph_Jimenez" title="Joseph Jimenez">Joseph Jimenez</a> <small>(<a href="/wiki/Chief_executive_officer" title="Chief executive officer">CEO</a>)</small></td>
</tr>
<tr>
<th scope="row" style="text-align:left;">Products</th>
<td><a href="/wiki/Pharmaceutical" title="Pharmaceutical" class="mw-redirect">Pharmaceuticals</a>, <a href="/wiki/Generic_drug" title="Generic drug">generic drugs</a>, <a href="/wiki/Over-the-counter_drug" title="Over-the-counter drug">over-the-counter drugs</a>, <a href="/wiki/Vaccine" title="Vaccine">vaccines</a>, <a href="/wiki/Medical_diagnosis" title="Medical diagnosis">diagnostics</a>, <a href="/wiki/Contact_lens" title="Contact lens">contact lenses</a>, <a href="/wiki/Veterinary_medicine" title="Veterinary medicine">animal health</a> (<a href="#Products">list...</a>)</td>
</tr>
<tr>
<th scope="row" style="text-align:left;">Revenue</th>
<td><span title="Increase"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" /></span> <a href="/wiki/United_States_dollar" title="United States dollar">US $</a>58.566 billion <small>(2011)</small><sup id="cite_ref-AR2010_1-0" class="reference"><a href="#cite_note-AR2010-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Earnings_before_interest_and_taxes" title="Earnings before interest and taxes">Operating income</a></th>
<td><span title="Decrease"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" /></span> US $10.998 billion <small>(2011)</small><sup id="cite_ref-AR2010_1-1" class="reference"><a href="#cite_note-AR2010-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Net_income" title="Net income">Net income</a></th>
<td><span title="Decrease"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" /></span> US $9.245 billion <small>(2011)</small><sup id="cite_ref-AR2010_1-2" class="reference"><a href="#cite_note-AR2010-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Asset" title="Asset">Total assets</a></th>
<td><span title="Decrease"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" /></span> US $117.496 billion <small>(2011)</small><sup id="cite_ref-AR2010_1-3" class="reference"><a href="#cite_note-AR2010-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Equity_(finance)" title="Equity (finance)">Total equity</a></th>
<td><span title="Decrease"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" /></span> US $65.940 billion <small>(2011)</small><sup id="cite_ref-AR2010_1-4" class="reference"><a href="#cite_note-AR2010-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="text-align:left;">Employees</th>
<td><span title="Increase"><img alt="Increase" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/11px-Increase2.svg.png" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/17px-Increase2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b0/Increase2.svg/22px-Increase2.svg.png 2x" /></span> 119,418 <small>(<a href="/wiki/Full-time_equivalent" title="Full-time equivalent">FTE</a>, end 2010)</small><sup id="cite_ref-AR2010_1-5" class="reference"><a href="#cite_note-AR2010-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="text-align:left;"><a href="/wiki/Subsidiary" title="Subsidiary">Subsidiaries</a></th>
<td>Ciba Vision, Sandoz, <a href="/wiki/Alcon" title="Alcon">Alcon</a>, <a href="/wiki/Chiron_Corporation" title="Chiron Corporation">Chiron Corporation</a></td>
</tr>
<tr>
<th scope="row" style="text-align:left;">Website</th>
<td><span class="url"><a rel="nofollow" class="external text" href="http://www.novartis.com/">www.novartis.com</a></span></td>
</tr>
</table>
<p><b>Novartis International AG</b> is a <a href="/wiki/Swiss" title="Swiss" class="mw-redirect">Swiss</a> <a href="/wiki/Multinational_corporation" title="Multinational corporation">multinational</a> <a href="/wiki/Pharmaceutical_company" title="Pharmaceutical company" class="mw-redirect">pharmaceutical company</a> based in <a href="/wiki/Basel,_Switzerland" title="Basel, Switzerland" class="mw-redirect">Basel, Switzerland</a>, ranking number two in <a href="/wiki/Pharmaceutical_company#Market_leaders_in_terms_of_sales" title="Pharmaceutical company" class="mw-redirect">sales</a> (46.806 billion US$) among the world-wide industry in 2010.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2"><span>[</span>2<span>]</span></a></sup></p>
<p>Novartis manufactures such drugs as <a href="/wiki/Clozapine" title="Clozapine">clozapine</a> (Clozaril), <a href="/wiki/Diclofenac" title="Diclofenac">diclofenac</a> (Voltaren), <a href="/wiki/Carbamazepine" title="Carbamazepine">carbamazepine</a> (Tegretol), <a href="/wiki/Valsartan" title="Valsartan">valsartan</a> (Diovan) and <a href="/wiki/Imatinib_mesylate" title="Imatinib mesylate" class="mw-redirect">imatinib mesylate</a> (Gleevec/Glivec). Additional agents include <a href="/wiki/Cyclosporin" title="Cyclosporin" class="mw-redirect">cyclosporin</a> (Neoral/Sandimmun), <a href="/wiki/Letrozole" title="Letrozole">letrozole</a> (Femara), <a href="/wiki/Methylphenidate" title="Methylphenidate">methylphenidate</a> (Ritalin), <a href="/wiki/Terbinafine" title="Terbinafine">terbinafine</a> (Lamisil), and others.</p>
<p>In 1996 <a href="/wiki/Ciba-Geigy" title="Ciba-Geigy" class="mw-redirect">Ciba-Geigy</a> merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like <a href="/wiki/Ciba_Specialty_Chemicals" title="Ciba Specialty Chemicals">Ciba Specialty Chemicals</a>, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its <a href="/wiki/Generic_drug" title="Generic drug">generic drugs</a> businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and <a href="/wiki/Genetically_modified_crops" title="Genetically modified crops">genetically modified crops</a> business in 2000 with the spinout of <a href="/wiki/Syngenta" title="Syngenta">Syngenta</a>, in partnership with <a href="/wiki/AstraZeneca" title="AstraZeneca">AstraZeneca</a> which also divested its agrochemical business.</p>
<p>Novartis is a full member of the <a href="/wiki/European_Federation_of_Pharmaceutical_Industries_and_Associations" title="European Federation of Pharmaceutical Industries and Associations">European Federation of Pharmaceutical Industries and Associations</a> (EFPIA)<sup id="cite_ref-3" class="reference"><a href="#cite_note-3"><span>[</span>3<span>]</span></a></sup> the <a href="/wiki/International_Federation_of_Pharmaceutical_Manufacturers_and_Associations" title="International Federation of Pharmaceutical Manufacturers and Associations" class="mw-redirect">International Federation of Pharmaceutical Manufacturers and Associations</a> (IFPMA),<sup id="cite_ref-4" class="reference"><a href="#cite_note-4"><span>[</span>4<span>]</span></a></sup> and the <a href="/wiki/Pharmaceutical_Research_and_Manufacturers_of_America" title="Pharmaceutical Research and Manufacturers of America">Pharmaceutical Research and Manufacturers of America</a> (PhRMA).<sup id="cite_ref-5" class="reference"><a href="#cite_note-5"><span>[</span>5<span>]</span></a></sup></p>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Corporate_structure"><span class="tocnumber">1</span> <span class="toctext">Corporate structure</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Place_in_its_market_segments"><span class="tocnumber">2</span> <span class="toctext">Place in its market segments</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#History"><span class="tocnumber">3</span> <span class="toctext">History</span></a>
<ul>
<li class="toclevel-2 tocsection-4"><a href="#Ciba-Geigy"><span class="tocnumber">3.1</span> <span class="toctext">Ciba-Geigy</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Sandoz_.28before_formation_of_Novartis.29"><span class="tocnumber">3.2</span> <span class="toctext">Sandoz (before formation of Novartis)</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#After_the_merger"><span class="tocnumber">3.3</span> <span class="toctext">After the merger</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-7"><a href="#Research"><span class="tocnumber">4</span> <span class="toctext">Research</span></a></li>
<li class="toclevel-1 tocsection-8"><a href="#Basel_headquarters_campus_redesign"><span class="tocnumber">5</span> <span class="toctext">Basel headquarters campus redesign</span></a></li>
<li class="toclevel-1 tocsection-9"><a href="#Products"><span class="tocnumber">6</span> <span class="toctext">Products</span></a>
<ul>
<li class="toclevel-2 tocsection-10"><a href="#Pharmaceuticals"><span class="tocnumber">6.1</span> <span class="toctext">Pharmaceuticals</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Consumer_health"><span class="tocnumber">6.2</span> <span class="toctext">Consumer health</span></a></li>
<li class="toclevel-2 tocsection-12"><a href="#Animal_health"><span class="tocnumber">6.3</span> <span class="toctext">Animal health</span></a>
<ul>
<li class="toclevel-3 tocsection-13"><a href="#Pet_Care"><span class="tocnumber">6.3.1</span> <span class="toctext">Pet Care</span></a></li>
<li class="toclevel-3 tocsection-14"><a href="#Livestock"><span class="tocnumber">6.3.2</span> <span class="toctext">Livestock</span></a></li>
<li class="toclevel-3 tocsection-15"><a href="#Bioprotection_.28insect_and_rodent_control.29"><span class="tocnumber">6.3.3</span> <span class="toctext">Bioprotection (insect and rodent control)</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-16"><a href="#Controversies_and_criticism"><span class="tocnumber">7</span> <span class="toctext">Controversies and criticism</span></a>
<ul>
<li class="toclevel-2 tocsection-17"><a href="#Challenge_to_India.27s_patent_laws"><span class="tocnumber">7.1</span> <span class="toctext">Challenge to India's patent laws</span></a></li>
<li class="toclevel-2 tocsection-18"><a href="#.22No.22_to_free_flu_vaccines"><span class="tocnumber">7.2</span> <span class="toctext">"No" to free flu vaccines</span></a></li>
<li class="toclevel-2 tocsection-19"><a href="#Sexual_discrimination_class_action_from_5.2C600_current_and_former_employees"><span class="tocnumber">7.3</span> <span class="toctext">Sexual discrimination class action from 5,600 current and former employees</span></a></li>
<li class="toclevel-2 tocsection-20"><a href="#Off-label_marketing_and_other_marketing_violations"><span class="tocnumber">7.4</span> <span class="toctext">Off-label marketing and other marketing violations</span></a></li>
<li class="toclevel-2 tocsection-21"><a href="#Fighting_off-label_prescribing_of_competitor.27s_drug"><span class="tocnumber">7.5</span> <span class="toctext">Fighting off-label prescribing of competitor's drug</span></a></li>
<li class="toclevel-2 tocsection-22"><a href="#Valsartan_data_scandal_in_Japan"><span class="tocnumber">7.6</span> <span class="toctext">Valsartan data scandal in Japan</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-23"><a href="#See_also"><span class="tocnumber">8</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-24"><a href="#References"><span class="tocnumber">9</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-25"><a href="#External_links"><span class="tocnumber">10</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Corporate_structure">Corporate structure</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=1" title="Edit section: Corporate structure">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Novartis AG is a Swiss, publicly traded, holding company that operates through the Novartis Group; Novartis AG owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group.<sup id="cite_ref-AR2012_6-0" class="reference"><a href="#cite_note-AR2012-6"><span>[</span>6<span>]</span></a></sup><sup class="reference" style="white-space:nowrap;">:117</sup></p>
<p>The businesses of Novartis are divided into six operating divisions: Pharmaceuticals, Alcon (eye care), Vaccines and Diagnostics, Sandoz (generics), Consumer (divided into two divisions: Over-the-Counter and Animal Health), and Corporate.<sup id="cite_ref-AR2012_6-1" class="reference"><a href="#cite_note-AR2012-6"><span>[</span>6<span>]</span></a></sup><sup class="reference" style="white-space:nowrap;">:150</sup> Novartis operates directly and through dozens of subsidiaries in countries around the world, each of which fall under one of the divisions, and that Novartis categorizes as fulfilling one or more of the following functions: "Holding/Finance: the entity is a holding company and/or performs finance functions for the Group; Sales: the entity performs sales and marketing activities for the Group; Production: the entity performs manufacturing and/or production activities for the Group; and Research: the entity performs research and development activities for the Group."<sup id="cite_ref-AR2012_6-2" class="reference"><a href="#cite_note-AR2012-6"><span>[</span>6<span>]</span></a></sup><sup class="reference" style="white-space:nowrap;">:251–253</sup></p>
<p>Novartis AG also holds 33.3% of the shares of <a href="/wiki/Hoffmann-La_Roche" title="Hoffmann-La Roche">Roche</a> however, it does not exercise control over Roche. Novartis also owns 24.9% of Idenix Pharmaceuticals but, again, does not exercise control over Idenix.<sup id="cite_ref-AR2012_6-3" class="reference"><a href="#cite_note-AR2012-6"><span>[</span>6<span>]</span></a></sup><sup class="reference" style="white-space:nowrap;">:117</sup> Novartis also has two significant license agreement with <a href="/wiki/Genentech" title="Genentech">Genentech</a>, a subsidiary of Roche. One agreement is for <a href="/wiki/Lucentis" title="Lucentis" class="mw-redirect">Lucentis</a>; the other is for <a href="/wiki/Xolair" title="Xolair" class="mw-redirect">Xolair</a>, both of which Novartis markets outside the US.<sup id="cite_ref-AR2012_6-4" class="reference"><a href="#cite_note-AR2012-6"><span>[</span>6<span>]</span></a></sup><sup class="reference" style="white-space:nowrap;">:239</sup></p>
<h2><span class="mw-headline" id="Place_in_its_market_segments">Place in its market segments</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=2" title="Edit section: Place in its market segments">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Overall, Novartis was the world's second largest pharmaceutical company in 2011, and was projected to take first place in 2018.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span>[</span>7<span>]</span></a></sup> An IMS Health report ranked Novartis as the biggest pharma company in 2012.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span>[</span>8<span>]</span></a></sup></p>
<p>Alcon: Alcon was already the world's largest and most profitable eye care company when Novartis bought it, with 2009 annual sales of $6.5 billion and net income of $2 billion. At that time, Novartis stated that it believed the two companies could generate approximately $200 million of potential annual pre-tax cost synergies.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9"><span>[</span>9<span>]</span></a></sup></p>
<p>Sandoz: As of 2013<sup class="plainlinks noprint asof-tag update" style="display:none;"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Novartis&amp;action=edit">[update]</a></sup>, Sandoz was the world's second largest generic drug company, contributing US$1.09 billion to Novartis' operating profit on US$8.70 billion in revenue in 2012.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10"><span>[</span>10<span>]</span></a></sup> Sandoz' <a href="/wiki/Biosimilars" title="Biosimilars" class="mw-redirect">biosimilars</a> leads its field, getting the first biosimilar approvals in the EU.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11"><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-12" class="reference"><a href="#cite_note-12"><span>[</span>12<span>]</span></a></sup></p>
<p>Vaccines and Diagnostics: As of 2013<sup class="plainlinks noprint asof-tag update" style="display:none;"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Novartis&amp;action=edit">[update]</a></sup> Novartis was considering selling this division off. While "sales in the unit were up 14% for the first half of 2013, it reported an operating loss of $240 million in the first half of 2013 after a $250 million loss for all 2012.... Vaccine revenue was $1.4 billion in 2012 and has been forecast to more than double to $3.14 billion by 2018."<sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span>[</span>13<span>]</span></a></sup></p>
<p>Consumer: Novartis is not a leader in the over the counter or animal health segments; its leading OTC brands are <a href="/wiki/Excedrin" title="Excedrin">Excedrin</a> and <a href="/wiki/Theraflu" title="Theraflu">Theraflu</a>, but sales have been slowed by problems at its key US manufacturing plant.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span>[</span>14<span>]</span></a></sup></p>
<p>In 2012, Novartis ranked 7th on the <a href="/wiki/Access_to_Medicine_Index" title="Access to Medicine Index">Access to Medicine Index</a>,<sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span>[</span>15<span>]</span></a></sup><sup class="reference" style="white-space:nowrap;">:88</sup> which "ranks companies on how readily they make their products available to the world’s poor."<sup id="cite_ref-NYTindex_16-0" class="reference"><a href="#cite_note-NYTindex-16"><span>[</span>16<span>]</span></a></sup> In 2010, Novartis was in the top three pharma companies (as it was in 2008).<sup id="cite_ref-NYTindex_16-1" class="reference"><a href="#cite_note-NYTindex-16"><span>[</span>16<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=3" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:252px;"><a href="/wiki/File:Industria_Novartis.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/2/24/Industria_Novartis.jpg/250px-Industria_Novartis.jpg" width="250" height="188" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/24/Industria_Novartis.jpg/375px-Industria_Novartis.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/24/Industria_Novartis.jpg/500px-Industria_Novartis.jpg 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Industria_Novartis.jpg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf20/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Novartis AG headquarters in <a href="/wiki/Basel" title="Basel">Basel</a></div>
</div>
</div>
<p>Novartis was created in 1996 from the merger of <b>Ciba-Geigy</b> and <b>Sandoz Laboratories</b>, both Swiss companies with long histories. Ciba-Geigy was formed in 1970 by the merger of <b>J. R. Geigy Ltd</b> (founded in Basel in 1758) and <b>CIBA</b> (founded in Basel in 1859). Combining the histories of the merger partners, the company's effective history spans 250 years.<sup id="cite_ref-novhist_17-0" class="reference"><a href="#cite_note-novhist-17"><span>[</span>17<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Ciba-Geigy">Ciba-Geigy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=4" title="Edit section: Ciba-Geigy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In 1859, Alexander Clavel (1805–1873) took up the production of <a href="/wiki/Fuchsine" title="Fuchsine">fuchsine</a> in his factory for <a href="/wiki/Silk" title="Silk">silk</a>-dyeing works in Basel. In 1864, a new site for the production of synthetic dyes was constructed, and in 1873, Clavel sold his dye factory to the new company Bindschedler and Busch. In 1884, Bindschedler and Busch was transformed into a joint-stock company with the name "Gesellschaft für Chemische Industrie Basel" (Company for Chemical Industry Basel). The <a href="/wiki/Acronym" title="Acronym">acronym</a>, CIBA, was adopted as the company's name in 1945.</p>
<p>Johann Rudolf Geigy-Gemuseus (1733–1793) began trading in 1758 in "materials, chemicals, dyes and drugs of all kinds"<sup id="cite_ref-18" class="reference"><a href="#cite_note-18"><span>[</span>18<span>]</span></a></sup><sup id="cite_ref-MinRec_19-0" class="reference"><a href="#cite_note-MinRec-19"><span>[</span>19<span>]</span></a></sup> in <a href="/wiki/Basel" title="Basel">Basel</a>, <a href="/wiki/Switzerland" title="Switzerland">Switzerland</a>. Johann Rudolf Geigy-Merian (1830–1917) and Johann Muller-Pack acquired a site in Basel in 1857, where they built a <a href="/wiki/Dyewood" title="Dyewood" class="mw-redirect">dyewood</a> mill and a <a href="/wiki/Dye" title="Dye">dye</a> extraction plant. Two years later, they began the production of synthetic <a href="/wiki/Fuchsine" title="Fuchsine">fuchsine</a>. In 1901, they formed the <a href="/wiki/Public_limited_company" title="Public limited company">public limited company</a> Geigy and the name of the company was changed to J. R. Geigy Ltd in 1914.</p>
<p>In 1925, J. R. Geigy Ltd. began producing textile auxiliaries,<sup id="cite_ref-20" class="reference"><a href="#cite_note-20"><span>[</span>20<span>]</span></a></sup> an activity which Ciba took up in 1928.</p>
<p>In 1939, Geigy chemist <a href="/wiki/Paul_Hermann_M%C3%BCller" title="Paul Hermann Müller">Paul Hermann Müller</a> discovered that <a href="/wiki/DDT" title="DDT">DDT</a> was effective against malaria-bearing insects. He received the 1948 <a href="/wiki/Nobel_Prize_in_Medicine" title="Nobel Prize in Medicine" class="mw-redirect">Nobel Prize in Medicine</a> for this work.</p>
<p>CIBA and Geigy merged in 1971 to form Ciba‑Geigy Ltd. <span class="nowrap"><span title="Representation in the International Phonetic Alphabet (IPA)" class="IPA"><a href="/wiki/Help:IPA_for_English" title="Help:IPA for English">/</a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/ˌ/ secondary stress follows" style="border-bottom:1px dotted">ˌ</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'s' in 'sigh'" style="border-bottom:1px dotted">s</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/iː/ long 'e' in 'bead'" style="border-bottom:1px dotted">iː</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'b' in 'buy'" style="border-bottom:1px dotted">b</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/ə/ 'a' in 'about'" style="border-bottom:1px dotted">ə</span></a></span> <span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/ˈ/ primary stress follows" style="border-bottom:1px dotted">ˈ</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'g' in 'guy'" style="border-bottom:1px dotted">ɡ</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/aɪ/ long 'i' in 'bide'" style="border-bottom:1px dotted">aɪ</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'g' in 'guy'" style="border-bottom:1px dotted">ɡ</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/i/ 'y' in 'happy'" style="border-bottom:1px dotted">i</span></a></span><span title="Representation in the International Phonetic Alphabet (IPA)" class="IPA"><a href="/wiki/Help:IPA_for_English" title="Help:IPA for English">/</a></span></span>. In the United States, the Geigy staff relocated to join the CIBA staff at its American headquarters for research in <a href="/wiki/Ardsley,_New_York" title="Ardsley, New York">Ardsley, New York</a>.</p>
<p>In 1980, Ciba-Geigy set up the company, Ciba Vision, to enter the contact lens market.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span>[</span>21<span>]</span></a></sup></p>
<p>In 1992 Ciba-Geigy agreed to pay New Jersey $62 million for illegal waste dumping.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22"><span>[</span>22<span>]</span></a></sup></p>
<p>In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were spun off as independent companies.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23"><span>[</span>23<span>]</span></a></sup><sup id="cite_ref-NYTmerger_24-0" class="reference"><a href="#cite_note-NYTmerger-24"><span>[</span>24<span>]</span></a></sup> Notably, <a href="/wiki/Ciba_Specialty_Chemicals" title="Ciba Specialty Chemicals">Ciba Specialty Chemicals</a> was spun out as an independent company,<sup id="cite_ref-NYTmerger_24-1" class="reference"><a href="#cite_note-NYTmerger-24"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-Fisher_25-0" class="reference"><a href="#cite_note-Fisher-25"><span>[</span>25<span>]</span></a></sup> and "Sandoz's Master Builders Technologies, a producer of chemicals for the construction industry, (was sold off) to SKW Trostberg A.G., a subsidiary of the German energy company Viag, and its North American corn herbicide business (was sold off) to the German chemical maker BASF A.G."<sup id="cite_ref-Fisher_25-1" class="reference"><a href="#cite_note-Fisher-25"><span>[</span>25<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Sandoz_.28before_formation_of_Novartis.29">Sandoz (before formation of Novartis)</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=5" title="Edit section: Sandoz (before formation of Novartis)">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Before the 1996 merger with <a href="/wiki/Ciba-Geigy" title="Ciba-Geigy" class="mw-redirect">Ciba-Geigy</a> to form Novartis, Sandoz Pharmaceuticals (Sandoz AG) was a <a href="/wiki/Pharmaceutical" title="Pharmaceutical" class="mw-redirect">pharmaceutical</a> company headquartered in <a href="/wiki/Basel" title="Basel">Basel</a>, <a href="/wiki/Switzerland" title="Switzerland">Switzerland</a> (as was Ciba-Geigy), and was best known for developing drugs such as <a href="/wiki/Sandimmune" title="Sandimmune" class="mw-redirect">Sandimmune</a> for <a href="/wiki/Organ_transplantation" title="Organ transplantation">organ transplantation</a>, the <a href="/wiki/Antipsychotic" title="Antipsychotic">antipsychotic</a> <a href="/wiki/Clozaril" title="Clozaril" class="mw-redirect">Clozaril</a>, <a href="/wiki/Mellaril" title="Mellaril" class="mw-redirect">Mellaril</a> Tablets and <a href="/wiki/Serentil" title="Serentil" class="mw-redirect">Serentil</a> Tablets for treating <a href="/wiki/Psychiatric_disorders" title="Psychiatric disorders" class="mw-redirect">psychiatric disorders</a>, and <a href="/wiki/Cafergot" title="Cafergot">Cafergot</a> Tablets and <a href="/wiki/Torecan" title="Torecan" class="mw-redirect">Torecan</a> Suppositories for treating <a href="/wiki/Migraine_headaches" title="Migraine headaches" class="mw-redirect">migraine headaches</a>.</p>
<p>The <i>Chemiefirma Kern und Sandoz</i> ("Kern and Sandoz Chemistry Firm") was founded in 1886 by <a href="/wiki/Alfred_Kern" title="Alfred Kern">Alfred Kern</a> (1850–1893) and Edouard Sandoz (1853–1928). The first dyes manufactured by them were <a href="/wiki/Alizarin" title="Alizarin">alizarinblue</a> and <a href="/wiki/Auramine" title="Auramine" class="mw-redirect">auramine</a>. After Kern's death, the partnership became the corporation <i>Chemische Fabrik vormals Sandoz</i> in 1895. The company began producing the fever-reducing drug <a href="/wiki/Antipyrin" title="Antipyrin" class="mw-redirect">antipyrin</a> in the same year. In 1899, the company began producing the sugar substitute, <a href="/wiki/Saccharin" title="Saccharin">saccharin</a>. Further pharmaceutical research began in 1917 under <a href="/wiki/Arthur_Stoll" title="Arthur Stoll">Arthur Stoll</a> (1887–1971), who is the founder of Sandoz's pharmaceutical department in 1917.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26"><span>[</span>26<span>]</span></a></sup> In 1918, Arthur Stoll isolates <a href="/wiki/Ergotamine" title="Ergotamine">ergotamine</a> from <a href="/wiki/Ergot" title="Ergot">ergot</a>; the substance is eventually used to treat migraine and headeaches and is introduced under the trade name Gynergen in 1921.</p>
<p>Between the World Wars, Gynergen (1921) and Calcium-Sandoz (1929) were brought to market. Sandoz also produced chemicals for <a href="/wiki/Textile" title="Textile">textiles</a>, <a href="/wiki/Paper" title="Paper">paper</a>, and <a href="/wiki/Leather" title="Leather">leather</a>, beginning in 1929. In 1939, the company began producing agricultural chemicals.</p>
<p>The <a href="/wiki/Psychedelic" title="Psychedelic" class="mw-redirect">psychedelic</a> effects of <a href="/wiki/Lysergic_acid_diethylamide" title="Lysergic acid diethylamide">lysergic acid diethylamide</a> (LSD) were discovered at the Sandoz laboratories in 1943 by <a href="/wiki/Arthur_Stoll" title="Arthur Stoll">Arthur Stoll</a> and <a href="/wiki/Albert_Hofmann" title="Albert Hofmann">Albert Hofmann</a>.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27"><span>[</span>27<span>]</span></a></sup><sup id="cite_ref-28" class="reference"><a href="#cite_note-28"><span>[</span>28<span>]</span></a></sup> Sandoz began clinical trials and marketed the substance, from 1947 through the mid-1960s, under the name <i>Delysid</i> as a <a href="/wiki/Psychiatry" title="Psychiatry">psychiatric</a> drug, thought useful for treating a wide variety of <a href="/wiki/Mental_disorder" title="Mental disorder">mental ailments</a>, ranging from <a href="/wiki/Alcoholism" title="Alcoholism">alcoholism</a> to <a href="/wiki/Sexual_deviancy" title="Sexual deviancy" class="mw-redirect">sexual deviancy</a>. Sandoz suggested in its marketing literature that psychiatrists take LSD themselves,<sup id="cite_ref-29" class="reference"><a href="#cite_note-29"><span>[</span>29<span>]</span></a></sup> to gain a better subjective understanding of the <a href="/wiki/Schizophrenia" title="Schizophrenia">schizophrenic</a> experience, and many did exactly that and so did other scientific researchers. The Sandoz product received mass publicity as early as 1954, in a <a href="/wiki/Time_Magazine" title="Time Magazine" class="mw-redirect">Time Magazine</a> feature.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30"><span>[</span>30<span>]</span></a></sup> Research on LSD peaked in the 1950s and early 1960s. Sandoz withdrew the drug from the market in the mid-1960s. The drug became a cultural novelty of the 1960s after psychologist <a href="/wiki/Timothy_Leary" title="Timothy Leary">Timothy Leary</a> at <a href="/wiki/Harvard_University" title="Harvard University">Harvard University</a> began to promulgate its use for recreational and spiritual experiences among the general public.</p>
<p>Sandoz opened its first foreign offices in 1964.</p>
<p>In 1967, Sandoz merged with Wander AG (known for <a href="/wiki/Ovomaltine" title="Ovomaltine" class="mw-redirect">Ovomaltine</a> and <a href="/wiki/Isostar" title="Isostar">Isostar</a>). Sandoz acquired the companies <a href="/wiki/Delmark" title="Delmark" class="mw-redirect">Delmark</a>, <a href="/wiki/Wasabr%C3%B6d" title="Wasabröd">Wasabröd</a> (a <a href="/wiki/Sweden" title="Sweden">Swedish</a> manufacturer of <a href="/wiki/Crisp_bread" title="Crisp bread">crisp bread</a>), and <a href="/wiki/Gerber_Products_Company" title="Gerber Products Company">Gerber Products Company</a> (a <a href="/wiki/Baby_food" title="Baby food">baby food</a> company).</p>
<p>On 1 November 1986, a fire broke out in a production plant storage room, which led to <a href="/wiki/Sandoz_chemical_spill" title="Sandoz chemical spill">Sandoz chemical spill</a> and a large amount of <a href="/wiki/Pesticide" title="Pesticide">pesticide</a> being released into the upper <a href="/wiki/Rhine" title="Rhine">Rhine</a> river. This exposure killed many fish and other aquatic life.</p>
<p>In 1995, Sandoz spun off its <a href="/wiki/Specialty_chemicals" title="Specialty chemicals" class="mw-redirect">specialty chemicals</a> business to form <a href="/wiki/Clariant" title="Clariant">Clariant</a>. Subsequently, in 1997, Clariant merged with the specialty chemicals business that was spun off from <a href="/wiki/Hoechst_AG" title="Hoechst AG">Hoechst AG</a> in <a href="/wiki/Germany" title="Germany">Germany</a>.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31"><span>[</span>31<span>]</span></a></sup></p>
<p>In 1996 Sandoz merged with Ciba-Geigy, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis.</p>
<h3><span class="mw-headline" id="After_the_merger">After the merger</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=6" title="Edit section: After the merger">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:252px;"><a href="/wiki/File:Novartis.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/3/31/Novartis.jpg/250px-Novartis.jpg" width="250" height="108" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/3/31/Novartis.jpg/375px-Novartis.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/31/Novartis.jpg/500px-Novartis.jpg 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Novartis.jpg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf20/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<a href="/wiki/Suffern,_New_York" title="Suffern, New York">Suffern, New York</a>: one of the <b>Novartis</b> pharmaceutical production facilities in the United States</div>
</div>
</div>
<p>In 1998, the company made headlines with its <a href="/wiki/Biotechnology" title="Biotechnology">biotechnology</a> licensing agreement with the <a href="/wiki/UC_Berkeley" title="UC Berkeley" class="mw-redirect">University of California at Berkeley</a> Department of Plant and <a href="/wiki/Microbe" title="Microbe" class="mw-redirect">Microbial</a> <a href="/wiki/Biology" title="Biology">Biology</a>. Critics of the agreement expressed concern over prospects that the agreement would diminish academic objectivity, or lead to the commercialization of <a href="/wiki/Genetically_modified" title="Genetically modified" class="mw-redirect">genetically modified</a> plants. The agreement expired in 2003.</p>
<p>In 2000 Novartis and <a href="/wiki/AstraZeneca" title="AstraZeneca">AstraZeneca</a> combined their <a href="/wiki/Agrobusiness" title="Agrobusiness" class="mw-redirect">agrobusiness</a> divisions to create a new company, <a href="/wiki/Syngenta" title="Syngenta">Syngenta</a>.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32"><span>[</span>32<span>]</span></a></sup><sup id="cite_ref-33" class="reference"><a href="#cite_note-33"><span>[</span>33<span>]</span></a></sup></p>
<p>In 2003, Novartis organized all its generics businesses into one division, and merged some of its subsidiaries into one company, reusing the predecessor brand name of Sandoz.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34"><span>[</span>34<span>]</span></a></sup></p>
<p>In 2005, Novartis expanded its subsidiary Sandoz significantly though the US$8.29 billion acquisition of Hexal, one of Germany's leading <a href="/wiki/Generic_drug" title="Generic drug">generic drug</a> companies, and Eon Labs, a fast-growing United States generic pharmaceutical company.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35"><span>[</span>35<span>]</span></a></sup></p>
<p>In 2006, Novartis acquired the California-based <a href="/wiki/Chiron_Corporation" title="Chiron Corporation">Chiron Corporation</a>. Chiron formerly was divided into three units: Chiron Vaccines, Chiron Blood Testing, and Chiron BioPharmaceuticals. The biopharmaceutical unit was integrated into Novartis Pharmaceuticals, while the vaccines and blood testing units were made into a new Novartis Vaccines and Diagnostics division.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36"><span>[</span>36<span>]</span></a></sup></p>
<p>Also in 2006, Sandoz became the first company to have a <a href="/wiki/Biosimilar" title="Biosimilar">biosimilar</a> drug approved in Europe with its recombinant <a href="/wiki/Human_growth_hormone" title="Human growth hormone" class="mw-redirect">human growth hormone</a> drug.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37"><span>[</span>37<span>]</span></a></sup></p>
<p>In 2007, Novartis sold the <a href="/wiki/Gerber_Products_Company" title="Gerber Products Company">Gerber Products Company</a> to <a href="/wiki/Nestl%C3%A9" title="Nestlé">Nestlé</a> in 2007 as part of its continuing effort to shed old Sandoz and Ciba-Geigy businesses and focus on healthcare.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38"><span>[</span>38<span>]</span></a></sup></p>
<p>In 2009, Novartis reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the Group's limited presence in this fast-growing market segment. This proposed acquisition will require government and regulatory approvals in China.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39"><span>[</span>39<span>]</span></a></sup></p>
<p>In 2010, Novartis offered to pay US $39.3 billion to fully acquire <a href="/wiki/Alcon" title="Alcon">Alcon</a>, the world's largest eye-care company, including a majority stake held by <a href="/wiki/Nestl%C3%A9" title="Nestlé">Nestlé</a>. Novartis had bought 25% of Alcon in 2008.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40"><span>[</span>40<span>]</span></a></sup> Novartis created a new division and called it Alcon, under which it placed its CIBA VISION subsidiary and Novartis Ophthalmics, which became the second-largest division of Novartis.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41"><span>[</span>41<span>]</span></a></sup></p>
<p>In 2011, Novartis acquired the medical laboratory diagnostics company Genoptix to "serve as a strong foundation for our (Novartis') individualized treatment programs".<sup id="cite_ref-42" class="reference"><a href="#cite_note-42"><span>[</span>42<span>]</span></a></sup></p>
<p>In 2012, the Company cut ~2000 positions in the United States, most in sales, in response to anticipated revenue downturns from the <a href="/wiki/Hypertension" title="Hypertension">hypertension</a> drug <a href="/wiki/Diovan" title="Diovan" class="mw-redirect">Diovan</a>, which was losing patent protection, and the realization that the anticipated successor to Diovan, <a href="/wiki/Rasilez" title="Rasilez" class="mw-redirect">Rasilez</a>, was failing in clinical trials.<sup id="cite_ref-APjp2012_43-0" class="reference"><a href="#cite_note-APjp2012-43"><span>[</span>43<span>]</span></a></sup> The 2012 personnel reductions follow ~2000 cut positions in Switzerland and the United States in 2011, ~1400 cut positions in the United States in 2010, and a reduction of "thousands" and several site closures in previous years.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44"><span>[</span>44<span>]</span></a></sup></p>
<p>Also in 2012, Novartis became the biggest manufacturer of generic skin care medicine, after agreed to buy Fougera Pharmaceuticals for $1.525 billion in cash.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45"><span>[</span>45<span>]</span></a></sup></p>
<p>In 2013, <a href="/wiki/Novartis_v._Union_of_India_%26_Others" title="Novartis v. Union of India &amp; Others">the Indian Supreme Court issued a decision</a> rejecting Novartis' patent application in India on the final form of <a href="/wiki/Gleevec" title="Gleevec" class="mw-redirect">Gleevec</a>, Novartis's cancer drug; the case caused great controversy.<sup id="cite_ref-46" class="reference"><a href="#cite_note-46"><span>[</span>46<span>]</span></a></sup></p>
<p>In 2013, Novartis was sued again by the US government, this time for allegedly bribing doctors for a decade so that their patients are steered towards the company's drugs.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47"><span>[</span>47<span>]</span></a></sup></p>
<p>In January 2014, Novartis announced plans to cut 500 jobs from its pharmaceuticals division.<sup id="cite_ref-48" class="reference"><a href="#cite_note-48"><span>[</span>48<span>]</span></a></sup></p>
<p>In February 2014, Novartis announced that it has acquired CoStim Pharmaceuticals.<sup id="cite_ref-49" class="reference"><a href="#cite_note-49"><span>[</span>49<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Research">Research</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=7" title="Edit section: Research">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The company's global research operations, called "Novartis Institutes for BioMedical Research (NIBR)" have their global headquarters in <a href="/wiki/Cambridge,_Massachusetts" title="Cambridge, Massachusetts">Cambridge, Massachusetts</a>.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50"><span>[</span>50<span>]</span></a></sup><sup id="cite_ref-51" class="reference"><a href="#cite_note-51"><span>[</span>51<span>]</span></a></sup> Two research institutes reside within NIBR that focus on diseases in the developing world: Novartis Institute for Tropical Diseases, which works on tuberculosis, dengue, and malariam and Novartis Vaccines Institute for Global Health, which works on salmonella typhi (Typhoid Fever) and Shigella.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52"><span>[</span>52<span>]</span></a></sup></p>
<p>Novartis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of <a href="/wiki/Pre-clinical_development" title="Pre-clinical development">non-clinical</a> safety assessment is the InnoMed PredTox project.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53"><span>[</span>53<span>]</span></a></sup><sup id="cite_ref-InnoMed_PredTox_official_project_website_54-0" class="reference"><a href="#cite_note-InnoMed_PredTox_official_project_website-54"><span>[</span>54<span>]</span></a></sup> The company is expanding its activities in joint research projects within the framework of the <a href="/wiki/Innovative_Medicines_Initiative" title="Innovative Medicines Initiative">Innovative Medicines Initiative</a> of <a href="/wiki/EFPIA" title="EFPIA" class="mw-redirect">EFPIA</a> and the <a href="/wiki/European_Commission" title="European Commission">European Commission</a>.<sup id="cite_ref-IMI_Call_Topics_2008_55-0" class="reference"><a href="#cite_note-IMI_Call_Topics_2008-55"><span>[</span>55<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Basel_headquarters_campus_redesign">Basel headquarters campus redesign</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=8" title="Edit section: Basel headquarters campus redesign">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Novartis_building_-_83d40m_-_basel_-_frank-gehry_p2z.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/9/94/Novartis_building_-_83d40m_-_basel_-_frank-gehry_p2z.JPG/220px-Novartis_building_-_83d40m_-_basel_-_frank-gehry_p2z.JPG" width="220" height="172" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/en/thumb/9/94/Novartis_building_-_83d40m_-_basel_-_frank-gehry_p2z.JPG/330px-Novartis_building_-_83d40m_-_basel_-_frank-gehry_p2z.JPG 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/94/Novartis_building_-_83d40m_-_basel_-_frank-gehry_p2z.JPG/440px-Novartis_building_-_83d40m_-_basel_-_frank-gehry_p2z.JPG 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Novartis_building_-_83d40m_-_basel_-_frank-gehry_p2z.JPG" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf20/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<a href="/wiki/Human_resources" title="Human resources">Human resources</a> building of the new Basel campus of Novartis—designed by <a href="/wiki/Frank_Gehry" title="Frank Gehry">Frank Gehry</a></div>
</div>
</div>
<p>An ongoing Basel Campus Project has the aim to transform Novartis headquarters in Basel "from an industrial complex to a place of innovation, knowledge, and encounter".<sup id="cite_ref-novartis1_56-0" class="reference"><a href="#cite_note-novartis1-56"><span>[</span>56<span>]</span></a></sup> The pharmaceutical giant decided to transform the existing Sandoz office buildings and chemical factories of its headquarters in 2001.</p>
<p>The buildings gradually were demolished and replaced with works by architects and artists of international stature. <a href="/wiki/Frank_Gehry" title="Frank Gehry">Frank Gehry</a>, <a href="/wiki/Rafael_Moneo" title="Rafael Moneo">Rafael Moneo</a>, and from <a href="/wiki/SANAA" title="SANAA">SANAA</a>, <a href="/wiki/Kazuyo_Sejima" title="Kazuyo Sejima">Kazuyo Sejima</a> and <a href="/wiki/Ryue_Nishizawa" title="Ryue Nishizawa">Ryue Nishizawa</a> were among the architects and <a href="/wiki/Jenny_Holzer" title="Jenny Holzer">Jenny Holzer</a> and <a href="/wiki/Richard_Serra" title="Richard Serra">Richard Serra</a> among the artists. Marked diversity of forms now dominates the campus. Novel features and technologies were introduced by Gehry to conform to the building standards of the Swiss government that prohibit <a href="/wiki/Air-conditioning" title="Air-conditioning" class="mw-redirect">air-conditioning</a>, while still selecting a contemporary style of massive use of glass exteriors. One adaptation by the architect includes the integration of a building vent, <a href="/wiki/Teepee" title="Teepee" class="mw-redirect">teepee</a>-style, through the roof, which creates a chimney effect that draws cool air in at the lower levels and vents warmer air.</p>
<h2><span class="mw-headline" id="Products">Products</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=9" title="Edit section: Products">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Pharmaceuticals">Pharmaceuticals</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=10" title="Edit section: Pharmaceuticals">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<table class="wikitable sortable">
<tr>
<th>Name</th>
<th><a href="/wiki/Indication_(medicine)" title="Indication (medicine)">Indication(s)</a> or drug type/class</th>
<th>Sales <span style="white-space:nowrap;"><a href="/wiki/United_States_dollar" title="United States dollar">US$millions</a></span></th>
<th>Sales year</th>
<th>% Change</th>
<th>Notes</th>
</tr>
<tr>
<td>Aclasta / Reclast (<a href="/wiki/Zoledronic_acid" title="Zoledronic acid">zoledronic acid</a>)</td>
<td><a href="/wiki/Osteoporosis" title="Osteoporosis">Osteoporosis</a></td>
<td>590</td>
<td>2012<sup id="cite_ref-2012Sales_57-0" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>-4%</td>
<td></td>
</tr>
<tr>
<td>Adelphane-Esidrex (<a href="/wiki/Reserpine" title="Reserpine">reserpine</a>/<a href="/wiki/Dihydralazine" title="Dihydralazine">dihydralazine</a>/<a href="/wiki/Hydrochlorothiazide" title="Hydrochlorothiazide">hydrochlorothiazide</a>)</td>
<td><a href="/wiki/Hypertension" title="Hypertension">Hypertension</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Afinitor/Sertican/Zortress (<a href="/wiki/Everolimus" title="Everolimus">everolimus</a>)</td>
<td>Prevention of <a href="/wiki/Transplant_rejection" title="Transplant rejection">transplant rejection</a>, various cancers</td>
<td>797</td>
<td>2012<sup id="cite_ref-2012Sales_57-1" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>80%</td>
<td></td>
</tr>
<tr>
<td>Amturnide (<a href="/wiki/Aliskiren" title="Aliskiren">aliskiren</a>/<a href="/wiki/Amlodipine" title="Amlodipine">amlodipine</a>/hydrochlorothiazide)</td>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anafranil (<a href="/wiki/Clomipramine" title="Clomipramine">clomipramine</a>)</td>
<td><a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">Major depressive disorder</a>, <a href="/wiki/Obsessive-compulsive_disorder" title="Obsessive-compulsive disorder" class="mw-redirect">obsessive-compulsive disorder</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arcapta Neohaler/Onbrez Breezhaler (<a href="/wiki/Indacaterol" title="Indacaterol">indacaterol</a>)</td>
<td><a href="/wiki/COPD" title="COPD" class="mw-redirect">COPD</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brinaldix (<a href="/wiki/Clopamide" title="Clopamide">clopamide</a>)</td>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clozaril/Leponex (<a href="/wiki/Clozapine" title="Clozapine">clozapine</a>)</td>
<td>Treatment-resistant <a href="/wiki/Schizophrenia" title="Schizophrenia">schizophrenia</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coartem/Riamet (<a href="/wiki/Artemether/lumefantrine" title="Artemether/lumefantrine">artemether/lumefantrine</a>)</td>
<td>Malaria (uncomplicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comtan (<a href="/wiki/Entacapone" title="Entacapone">entacapone</a>)</td>
<td><a href="/wiki/Parkinson%27s_disease" title="Parkinson's disease">Parkinson's disease</a></td>
<td>530</td>
<td>2012<sup id="cite_ref-2012Sales_57-2" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>-14%</td>
<td></td>
</tr>
<tr>
<td>Diovan (<a href="/wiki/Valsartan" title="Valsartan">valsartan</a>)</td>
<td>Hypertension</td>
<td>4,417</td>
<td>2012<sup id="cite_ref-2012Sales_57-3" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>-22%</td>
<td></td>
</tr>
<tr>
<td>Eucreas/Galvus Met (<a href="/wiki/Vildagliptin" title="Vildagliptin">vildagliptin</a>/<a href="/wiki/Metformin" title="Metformin">metformin</a>)</td>
<td><a href="/wiki/Diabetes_mellitus_type_2" title="Diabetes mellitus type 2">Diabetes mellitus type 2</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exelon Patch (<a href="/wiki/Rivastigmine" title="Rivastigmine">rivastigmine</a>)</td>
<td><a href="/wiki/Alzheimer%27s_disease" title="Alzheimer's disease">Alzheimer's disease</a></td>
<td>1,050</td>
<td>2012<sup id="cite_ref-2012Sales_57-4" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>-2%</td>
<td></td>
</tr>
<tr>
<td>Exforge (<a href="/wiki/Amlodipine/valsartan" title="Amlodipine/valsartan">amlodipine/valsartan</a>)</td>
<td>Hypertension</td>
<td>1,352</td>
<td>2012<sup id="cite_ref-2012Sales_57-5" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>12%</td>
<td></td>
</tr>
<tr>
<td>Exjade (<a href="/wiki/Deferasirox" title="Deferasirox">deferasirox</a>)</td>
<td>Chronic <a href="/wiki/Iron_overload" title="Iron overload">iron overload</a></td>
<td>870</td>
<td>2012<sup id="cite_ref-2012Sales_57-6" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>Famvir (<a href="/wiki/Famciclovir" title="Famciclovir">famciclovir</a>)</td>
<td><a href="/wiki/Herpes_zoster" title="Herpes zoster">Herpes zoster</a> and other <i>Herpesvirus</i> infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fanapt (<a href="/wiki/Iloperidone" title="Iloperidone">iloperidone</a>)</td>
<td>Schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Femara (<a href="/wiki/Letrozole" title="Letrozole">letrozole</a>)</td>
<td><a href="/wiki/Breast_cancer" title="Breast cancer">Breast cancer</a></td>
<td>438</td>
<td>2012<sup id="cite_ref-2012Sales_57-7" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>-52%</td>
<td></td>
</tr>
<tr>
<td>Focalin (<a href="/wiki/Dexmethylphenidate" title="Dexmethylphenidate">dexmethylphenidate</a>)</td>
<td><a href="/wiki/ADHD" title="ADHD" class="mw-redirect">ADHD</a></td>
<td></td>
<td></td>
<td></td>
<td>First US generics of Focalin became available in 2007<sup id="cite_ref-58" class="reference"><a href="#cite_note-58"><span>[</span>58<span>]</span></a></sup> Focalin XR became available in 2012.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59"><span>[</span>59<span>]</span></a></sup></td>
</tr>
<tr>
<td>Foradil/Foradile (<a href="/wiki/Formoterol" title="Formoterol">formoterol</a>)</td>
<td><a href="/wiki/Asthma" title="Asthma">Asthma</a>, COPD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Galvus (<a href="/wiki/Vildagliptin" title="Vildagliptin">vildagliptin</a>)</td>
<td>Diabetes mellitus type 2</td>
<td>910</td>
<td>2012<sup id="cite_ref-2012Sales_57-8" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>39%</td>
<td></td>
</tr>
<tr>
<td>Gilenya (<a href="/wiki/Fingolimod" title="Fingolimod">fingolimod</a>)</td>
<td><a href="/wiki/Multiple_sclerosis" title="Multiple sclerosis">Multiple sclerosis</a></td>
<td>1,195</td>
<td>2012<sup id="cite_ref-2012Sales_57-9" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>142%</td>
<td></td>
</tr>
<tr>
<td>Gleevec/Glivec (<a href="/wiki/Imatinib" title="Imatinib">imatinib</a>)</td>
<td><a href="/wiki/Oncology" title="Oncology">Oncology</a>, <a href="/wiki/Chronic_myelogenous_leukemia" title="Chronic myelogenous leukemia">Chronic myelogenous leukemia</a></td>
<td>4,675</td>
<td>2012<sup id="cite_ref-2012Sales_57-10" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>Hygroton (<a href="/wiki/Chlortalidone" title="Chlortalidone">chlortalidone</a>)</td>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ilaris (<a href="/wiki/Canakinumab" title="Canakinumab">canakinumab</a>)</td>
<td><a href="/wiki/Cryopyrin-associated_periodic_syndrome" title="Cryopyrin-associated periodic syndrome">Cryopyrin-associated periodic syndrome</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jakavi/Jakafi (<a href="/wiki/Ruxolitinib" title="Ruxolitinib">ruxolitinib</a>)</td>
<td>Myelofibrosis (of intermediate to high risk)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamisil (<a href="/wiki/Terbinafine" title="Terbinafine">terbinafine</a>)</td>
<td>Fungal infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lescol (<a href="/wiki/Fluvastatin" title="Fluvastatin">fluvastatin</a>)</td>
<td><a href="/wiki/Hypercholesterolemia" title="Hypercholesterolemia">Hypercholesterolemia</a></td>
<td>665</td>
<td>2007<sup id="cite_ref-novartis2007sales_60-0" class="reference"><a href="#cite_note-novartis2007sales-60"><span>[</span>60<span>]</span></a></sup></td>
<td>-8%</td>
<td></td>
</tr>
<tr>
<td>Lioresal (<a href="/wiki/Baclofen" title="Baclofen">baclofen</a>)</td>
<td><a href="/wiki/Spasticity" title="Spasticity">Spasticity</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lotrel (<a href="/wiki/Amlodipine/benazepril" title="Amlodipine/benazepril">amlodipine/benazepril</a>)</td>
<td>Hypertension</td>
<td>748</td>
<td>2007<sup id="cite_ref-novartis2007sales_60-1" class="reference"><a href="#cite_note-novartis2007sales-60"><span>[</span>60<span>]</span></a></sup></td>
<td>-34%</td>
<td></td>
</tr>
<tr>
<td>Lucentis (<a href="/wiki/Ranibizumab" title="Ranibizumab">ranibizumab</a>)</td>
<td>Age-related <a href="/wiki/Macular_degeneration" title="Macular degeneration">macular degeneration</a></td>
<td>2,398</td>
<td>2012<sup id="cite_ref-2012Sales_57-11" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>17%</td>
<td></td>
</tr>
<tr>
<td>Ludiomil (<a href="/wiki/Maprotiline" title="Maprotiline">maprotiline</a>)</td>
<td>Major depressive disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mellaril (<a href="/wiki/Thioridazine" title="Thioridazine">thioridazine</a>)</td>
<td>Schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myfortic (<a href="/wiki/Mycophenolic_acid" title="Mycophenolic acid">mycophenolic acid</a>)</td>
<td>Prevention of transplant rejection</td>
<td>579</td>
<td>2012<sup id="cite_ref-2012Sales_57-12" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>12%</td>
<td></td>
</tr>
<tr>
<td>Navoban (<a href="/wiki/Tropisetron" title="Tropisetron">tropisetron</a>)</td>
<td><a href="/wiki/Chemotherapy-induced_nausea_and_vomiting" title="Chemotherapy-induced nausea and vomiting">Chemotherapy-induced nausea and vomiting</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritalin (<a href="/wiki/Methylphenidate" title="Methylphenidate">methylphenidate</a>)</td>
<td><a href="/wiki/ADHD" title="ADHD" class="mw-redirect">ADHD</a></td>
<td>554</td>
<td>2012<sup id="cite_ref-2012Sales_57-13" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>Sandimmune/Neoral (<a href="/wiki/Ciclosporin" title="Ciclosporin">ciclosporin</a>)</td>
<td>Prevention of transplant rejection</td>
<td>821</td>
<td>2012<sup id="cite_ref-2012Sales_57-14" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>-9%</td>
<td></td>
</tr>
<tr>
<td>Sandostatin (<a href="/wiki/Octreotide" title="Octreotide">octreotide</a>)</td>
<td><a href="/wiki/Acromegaly" title="Acromegaly">Acromegaly</a></td>
<td>1,512</td>
<td>2012<sup id="cite_ref-2012Sales_57-15" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>5%</td>
<td></td>
</tr>
<tr>
<td>Signifor (<a href="/wiki/Pasireotide" title="Pasireotide">Pasireotide</a>)</td>
<td><a href="/wiki/Cushing%27s_disease" title="Cushing's disease">Cushing's disease</a><sup id="cite_ref-61" class="reference"><a href="#cite_note-61"><span>[</span>61<span>]</span></a></sup><sup id="cite_ref-62" class="reference"><a href="#cite_note-62"><span>[</span>62<span>]</span></a></sup></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simulect (<a href="/wiki/Basiliximab" title="Basiliximab">basiliximab</a>)</td>
<td>Prevention of transplant rejection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sirdalud (<a href="/wiki/Tizanidine" title="Tizanidine">tizanidine</a>)</td>
<td>Spasticity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spersallerg (<a href="/wiki/Antazoline" title="Antazoline">antazoline</a>/<a href="/wiki/Tetrahydrozoline" title="Tetrahydrozoline">tetrahydrozoline</a>)</td>
<td><a href="/wiki/Allergic_conjunctivitis" title="Allergic conjunctivitis">Allergic conjunctivitis</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stalevo (<a href="/wiki/Carbidopa" title="Carbidopa">carbidopa</a>/<a href="/wiki/Levodopa" title="Levodopa" class="mw-redirect">levodopa</a>/<a href="/wiki/Entacapone" title="Entacapone">entacapone</a>)</td>
<td>Parkinson's disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tasigna (<a href="/wiki/Nilotinib" title="Nilotinib">nilotinib</a>)</td>
<td>Chronic myelogenous leukemia (first-line treatment<sup id="cite_ref-wsjtasigna2012_63-0" class="reference"><a href="#cite_note-wsjtasigna2012-63"><span>[</span>63<span>]</span></a></sup>)</td>
<td>998</td>
<td>2012<sup id="cite_ref-2012Sales_57-16" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>39%</td>
<td><a href="/wiki/NICE" title="NICE" class="mw-redirect">NICE</a> formulary approval, January 2012<sup id="cite_ref-wsjtasigna2012_63-1" class="reference"><a href="#cite_note-wsjtasigna2012-63"><span>[</span>63<span>]</span></a></sup></td>
</tr>
<tr>
<td>Tegretol (<a href="/wiki/Carbamazepine" title="Carbamazepine">carbamazepine</a>)</td>
<td><a href="/wiki/Epilepsy" title="Epilepsy">Epilepsy</a>, <a href="/wiki/Bipolar_disorder" title="Bipolar disorder">bipolar disorder</a></td>
<td>413</td>
<td>2007<sup id="cite_ref-novartis2007sales_60-2" class="reference"><a href="#cite_note-novartis2007sales-60"><span>[</span>60<span>]</span></a></sup></td>
<td>6%</td>
<td></td>
</tr>
<tr>
<td>Tekamlo (<a href="/wiki/Aliskiren/amlodipine" title="Aliskiren/amlodipine">aliskiren/amlodipine</a>)</td>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tekturna/Rasilez (<a href="/wiki/Aliskiren" title="Aliskiren">aliskiren</a>)</td>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Termalgin (<a href="/wiki/Paracetamol" title="Paracetamol">paracetamol</a>)</td>
<td>Fever, mild pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobi (<a href="/wiki/Tobramycin" title="Tobramycin">tobramycin</a>)</td>
<td>Prevention of <i>Pseudomonas aeruginosa</i> infection in <a href="/wiki/Cystic_fibrosis" title="Cystic fibrosis">cystic fibrosis</a></td>
<td>350 (US only)</td>
<td>2012<sup id="cite_ref-Teva2013_64-0" class="reference"><a href="#cite_note-Teva2013-64"><span>[</span>64<span>]</span></a></sup></td>
<td></td>
<td>Teva introduced generic in the US in 2013<sup id="cite_ref-Teva2013_64-1" class="reference"><a href="#cite_note-Teva2013-64"><span>[</span>64<span>]</span></a></sup></td>
</tr>
<tr>
<td>Tofranil (<a href="/wiki/Imipramine" title="Imipramine">imipramine</a>)</td>
<td>Major depressive disorder, <a href="/wiki/Enuresis" title="Enuresis">enuresis</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trileptal (<a href="/wiki/Oxcarbazepine" title="Oxcarbazepine">oxcarbazepine</a>)</td>
<td>Epilepsy, bipolar disorder</td>
<td>690 (US only)</td>
<td>2007<sup id="cite_ref-teva2007_65-0" class="reference"><a href="#cite_note-teva2007-65"><span>[</span>65<span>]</span></a></sup></td>
<td></td>
<td>Teva introduced generic in 2008<sup id="cite_ref-teva2007_65-1" class="reference"><a href="#cite_note-teva2007-65"><span>[</span>65<span>]</span></a></sup></td>
</tr>
<tr>
<td>Tyzeca/Sebivo (<a href="/wiki/Telbivudine" title="Telbivudine">telbivudine</a>)</td>
<td>Hepatitis B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visudyne (<a href="/wiki/Verteporfin" title="Verteporfin">verteporfin</a>)</td>
<td>Age-related macular degeneration (wet form)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voltaren (<a href="/wiki/Diclofenac" title="Diclofenac">diclofenac</a>)</td>
<td>Acute pain, inflammatory disorders (such as <a href="/wiki/Rheumatoid_arthritis" title="Rheumatoid arthritis">rheumatoid arthritis</a>)</td>
<td>759 (excl. OTC)</td>
<td>2012<sup id="cite_ref-2012Sales_57-17" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>-4%</td>
<td></td>
</tr>
<tr>
<td>Zometa (<a href="/wiki/Zoledronic_acid" title="Zoledronic acid">zoledronic acid</a>)</td>
<td>Prevention of bone fractures in cancer patients</td>
<td>1,288</td>
<td>2012<sup id="cite_ref-2012Sales_57-18" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>-13%</td>
<td></td>
</tr>
<tr>
<td>Xolair (<a href="/wiki/Omalizumab" title="Omalizumab">omalizumab</a>)</td>
<td>Asthma (moderate to severe)</td>
<td>504</td>
<td>2012<sup id="cite_ref-2012Sales_57-19" class="reference"><a href="#cite_note-2012Sales-57"><span>[</span>57<span>]</span></a></sup></td>
<td>4%</td>
<td></td>
</tr>
<tr>
<td>Zaditen (<a href="/wiki/Ketotifen" title="Ketotifen">ketotifen</a>)</td>
<td>Asthma, allergic conjunctivitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</table>
<h3><span class="mw-headline" id="Consumer_health">Consumer health</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=11" title="Edit section: Consumer health">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<ul>
<li><a href="/wiki/Benefiber" title="Benefiber" class="mw-redirect">Benefiber</a></li>
<li><a href="/w/index.php?title=Bialcol&amp;action=edit&amp;redlink=1" class="new" title="Bialcol (page does not exist)">Bialcol</a> Alcohol</li>
<li><a href="/wiki/Buckley%27s" title="Buckley's">Buckley's</a> cold and cough formula</li>
<li><a href="/wiki/Bufferin" title="Bufferin" class="mw-redirect">Bufferin</a></li>
<li><a href="/wiki/ChestEze" title="ChestEze">ChestEze</a></li>
<li><a href="/w/index.php?title=Comtrex&amp;action=edit&amp;redlink=1" class="new" title="Comtrex (page does not exist)">Comtrex</a> cold and cough</li>
<li><a href="/wiki/Penciclovir" title="Penciclovir">Denavir/Vectavir</a></li>
<li><a href="/wiki/Miconazole" title="Miconazole">Desenex</a></li>
<li><a href="/wiki/Doan%27s" title="Doan's" class="mw-redirect">Doan's</a> pain relief</li>
<li><a href="/wiki/Ex-Lax" title="Ex-Lax" class="mw-redirect">Ex-Lax</a></li>
<li><a href="/wiki/Excedrin" title="Excedrin">Excedrin</a></li>
<li><a href="/wiki/Fenistil" title="Fenistil" class="mw-redirect">Fenistil</a></li>
<li><a href="/wiki/Gas-X" title="Gas-X" class="mw-redirect">Gas-X</a></li>
<li><a href="/wiki/Habitrol" title="Habitrol" class="mw-redirect">Habitrol</a></li>
<li><a href="/wiki/Keri" title="Keri">Keri</a> skin care</li>
<li><a href="/wiki/Lamisil" title="Lamisil" class="mw-redirect">Lamisil</a> foot care</li>
<li><a href="/w/index.php?title=Lipactin&amp;action=edit&amp;redlink=1" class="new" title="Lipactin (page does not exist)">Lipactin</a> <a href="/wiki/Herpes_simplex" title="Herpes simplex">herpes</a> symptomatic treatment</li>
<li><a href="/wiki/Maalox" title="Maalox">Maalox</a></li>
<li><a href="/wiki/Nicotine_replacement_therapy" title="Nicotine replacement therapy">Nicotinell</a></li>
<li><a href="/wiki/No-doz" title="No-doz" class="mw-redirect">No-doz</a></li>
<li><a href="/wiki/Xylometazoline" title="Xylometazoline">Otrivine</a></li>
<li><a href="/wiki/Lansoprazole" title="Lansoprazole">Prevacid 24HR</a></li>
<li><a href="/wiki/Savlon" title="Savlon">Savlon</a></li>
<li><a href="/wiki/Tavist" title="Tavist" class="mw-redirect">Tavist</a></li>
<li><a href="/wiki/Theraflu" title="Theraflu">Theraflu</a></li>
<li>Triaminic</li>
<li><a href="/wiki/Tioconazole" title="Tioconazole">Vagistat</a></li>
<li><a href="/wiki/Tixylix" title="Tixylix">Tixylix</a></li>
<li><a href="/wiki/Diclofenac" title="Diclofenac">Voltaren</a></li>
</ul>
<p>In January 2009, the <a href="/wiki/United_States_Department_of_Health_and_Human_Services" title="United States Department of Health and Human Services">United States Department of Health and Human Services</a> awarded Novartis a $486 million contract for construction of the first U.S. plant to produce cell-based <a href="/wiki/Influenza_vaccine" title="Influenza vaccine">influenza vaccine</a>, to be located in <a href="/wiki/Holly_Springs,_North_Carolina" title="Holly Springs, North Carolina">Holly Springs, North Carolina</a>. The stated goal of this program is the capability of producing 150,000,000 doses of <a href="/wiki/Influenza_research#Pandemic_flu_vaccine_planning" title="Influenza research">pandemic vaccine</a> within six months of declaring a flu pandemic.<sup id="cite_ref-66" class="reference"><a href="#cite_note-66"><span>[</span>66<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Animal_health">Animal health</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=12" title="Edit section: Animal health">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<h4><span class="mw-headline" id="Pet_Care">Pet Care</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=13" title="Edit section: Pet Care">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul>
<li>Interceptor (<a href="/wiki/Milbemycin_oxime" title="Milbemycin oxime">Milbemycin oxime</a>), oral worm control product</li>
<li><a href="/wiki/Sentinel_Flavor_Tabs" title="Sentinel Flavor Tabs" class="mw-redirect">Sentinel Flavor Tabs</a> (Milbemycin oxime, <a href="/wiki/Lufenuron" title="Lufenuron">Lufenuron</a>), oral flea control product</li>
<li>Deramaxx (<a href="/wiki/Deracoxib" title="Deracoxib">Deracoxib</a>), oral treatment for pain and inflammation from osteoarthritis in dogs</li>
<li>Capstar (<a href="/wiki/Nitenpyram" title="Nitenpyram">Nitenpyram</a>), oral tablet for flea control</li>
<li>Milbemax (<a href="/wiki/Milbemycin_oxime" title="Milbemycin oxime">Milbemycin oxime</a>, <a href="/wiki/Praziquantel" title="Praziquantel">Praziquantel</a>), oral worm treatment</li>
<li>Program (<a href="/wiki/Lufenuron" title="Lufenuron">Lufenuron</a>), oral tablet for flea control</li>
</ul>
<h4><span class="mw-headline" id="Livestock">Livestock</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=14" title="Edit section: Livestock">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul>
<li>Acatalk Duostar (Fluazuron, <a href="/wiki/Ivermectin" title="Ivermectin">Ivermectin</a>), tick control for cattle</li>
<li>CLiK (Dicyclanil), blowfly control for sheep</li>
<li>Denagard (Tiamulin)</li>
<li>Fasinex (<a href="/wiki/Triclabendazole" title="Triclabendazole">Triclabendazole</a>)</li>
<li>ViraShield</li>
</ul>
<h4><span class="mw-headline" id="Bioprotection_.28insect_and_rodent_control.29">Bioprotection (insect and rodent control)</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=15" title="Edit section: Bioprotection (insect and rodent control)">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<ul>
<li>Actara (Thiamenthoxam)</li>
<li>Atrazine (<a href="/wiki/Atrazine" title="Atrazine">Atrazine</a>)</li>
<li>Larvadex (<a href="/wiki/Cyromazine" title="Cyromazine">Cyromazine</a>)</li>
<li>Neporex (<a href="/wiki/Cyromazine" title="Cyromazine">Cyromazine</a>)</li>
<li>Oxyfly (<a href="/wiki/Lambda-cyhalothrin" title="Lambda-cyhalothrin" class="mw-redirect">Lambda-cyhalothrin</a>))</li>
<li>Virusnip (<a href="/wiki/Potassium_monopersulfate" title="Potassium monopersulfate" class="mw-redirect">Potassium monopersulfate</a>)</li>
</ul>
<h2><span class="mw-headline" id="Controversies_and_criticism">Controversies and criticism</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=16" title="Edit section: Controversies and criticism">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Challenge_to_India.27s_patent_laws">Challenge to India's patent laws</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=17" title="Edit section: Challenge to India's patent laws">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="rellink relarticle mainarticle">Main article: <a href="/wiki/Novartis_v._Union_of_India_%26_Others" title="Novartis v. Union of India &amp; Others">Novartis v. Union of India &amp; Others</a></div>
<p>Novartis fought a seven year, controversial battle to patent <a href="/wiki/Imatinib" title="Imatinib">Gleevec</a> in India, and took the case all the way to the <a href="/wiki/Indian_Supreme_Court" title="Indian Supreme Court" class="mw-redirect">Indian Supreme Court</a>, where the patent application was finally rejected. The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the <a href="/wiki/World_Trade_Organization" title="World Trade Organization">World Trade Organization</a> and to abide by worldwide intellectual property standards under the <a href="/wiki/TRIPS" title="TRIPS" class="mw-redirect">TRIPS</a> agreement. As part of this agreement, India made changes to its patent law; the biggest of which was that prior to these changes, patents on products were not allowed, while afterwards they were, albeit with restrictions. These changes came into effect in 2005, so Novartis' patent application waited in a "mailbox" with others until then, under procedures that India instituted to manage the transition. India also passed certain amendments to its patent law in 2005, just before the laws came into effect, which played a key role in the rejection of the patent application.<sup id="cite_ref-NYTreact_67-0" class="reference"><a href="#cite_note-NYTreact-67"><span>[</span>67<span>]</span></a></sup></p>
<p>The patent application<sup id="cite_ref-68" class="reference"><a href="#cite_note-68"><span>[</span>68<span>]</span></a></sup><sup id="cite_ref-PCT_69-0" class="reference"><a href="#cite_note-PCT-69"><span>[</span>69<span>]</span></a></sup> claimed the final form of Gleevec (the beta crystalline form of imatinib <a href="/wiki/Mesylate" title="Mesylate">mesylate</a>).<sup id="cite_ref-70" class="reference"><a href="#cite_note-70"><span>[</span>70<span>]</span></a></sup><sup class="reference" style="white-space:nowrap;">:3</sup> In 1993, during the time India did not allow patents on products, Novartis had patented imatinib, with <a href="/wiki/Salt_(chemistry)" title="Salt (chemistry)">salts</a> vaguely specified, in many countries but could not patent it in India.<sup id="cite_ref-71" class="reference"><a href="#cite_note-71"><span>[</span>71<span>]</span></a></sup><sup id="cite_ref-72" class="reference"><a href="#cite_note-72"><span>[</span>72<span>]</span></a></sup> The key differences between the two patent applications, were that 1998 patent application specified the <a href="/wiki/Counterion" title="Counterion">counterion</a> (Gleevec is a specific salt - imatinib mesylate) while the 1993 patent application did not claim any specific salts nor did it mention mesylate, and the 1998 patent application specified the solid form of Gleevec - the way the individual molecules are packed together into a solid when the <a href="/wiki/Active_ingredient" title="Active ingredient">drug itself</a> is manufactured (this is separate from processes by which the drug itself is <a href="/wiki/Pharmaceutical_formulation" title="Pharmaceutical formulation">formulated</a> into pills or capsules) - while the 1993 patent application did not. The solid form of imatinib mesylate in Gleevec is beta crystalline.<sup id="cite_ref-73" class="reference"><a href="#cite_note-73"><span>[</span>73<span>]</span></a></sup></p>
<p>As provided under the TRIPS agreement, Novartis applied for Exclusive Marketing Rights (EMR) for Gleevec from the Indian Patent Office and the EMR was granted in November 2003.<sup id="cite_ref-Decision8-9_74-0" class="reference"><a href="#cite_note-Decision8-9-74"><span>[</span>74<span>]</span></a></sup> Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India.<sup id="cite_ref-SpicyIP1_75-0" class="reference"><a href="#cite_note-SpicyIP1-75"><span>[</span>75<span>]</span></a></sup> Novartis set the price of Gleevec at USD 2666 per patient per month; generic companies were selling their versions at USD 177 to 266 per patient per month.<sup id="cite_ref-76" class="reference"><a href="#cite_note-76"><span>[</span>76<span>]</span></a></sup> Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch.<sup id="cite_ref-WSJ_77-0" class="reference"><a href="#cite_note-WSJ-77"><span>[</span>77<span>]</span></a></sup></p>
<p>When examination of Novartis' patent application began in 2005, it came under immediate attack from <a href="/wiki/Opposition_proceeding" title="Opposition proceeding">oppositions</a> initiated by generic companies that were already selling Gleevec in India and by advocacy groups. The application was rejected by the patent office and by an appeal board. The key basis for the rejection was the part of Indian patent law that was created by amendment in 2005, describing the patentability of new uses for known drugs and modifications of known drugs. That section, Paragraph 3d, specified that such inventions are patentable only if "they differ significantly in properties with regard to efficacy."<sup id="cite_ref-SpicyIP1_75-1" class="reference"><a href="#cite_note-SpicyIP1-75"><span>[</span>75<span>]</span></a></sup><sup id="cite_ref-Appellate_78-0" class="reference"><a href="#cite_note-Appellate-78"><span>[</span>78<span>]</span></a></sup> At one point, Novartis went to court to try to invalidate Paragraph 3d; it argued that the provision was unconstitutionally vague and that it violated TRIPS. Novartis lost that case and did not appeal.<sup id="cite_ref-2007Decn_79-0" class="reference"><a href="#cite_note-2007Decn-79"><span>[</span>79<span>]</span></a></sup> Novartis did appeal the rejection by the patent office to India's Supreme Court, which took the case.</p>
<p>The Supreme Court case hinged on the interpretation of Paragraph 3d. The Supreme Court decided that the substance that Novartis sought to patent was indeed a modification of a known drug (the raw form of imatinib, which was publicly disclosed in the 1993 patent application and in scientific articles), that Novartis did not present evidence of a difference in therapeutic efficacy between the final form of Gleevec and the raw form of imatinib, and that therefore the patent application was properly rejected by the patent office and lower courts.<sup id="cite_ref-80" class="reference"><a href="#cite_note-80"><span>[</span>80<span>]</span></a></sup></p>
<p>Although the court ruled narrowly,<sup id="cite_ref-81" class="reference"><a href="#cite_note-81"><span>[</span>81<span>]</span></a></sup> and took care to note that the subject application was filed during a time of transition in Indian patent law,<sup id="cite_ref-Decision24_82-0" class="reference"><a href="#cite_note-Decision24-82"><span>[</span>82<span>]</span></a></sup> the decision generated widespread global news coverage and reignited debates on balancing public good with monopolistic pricing, innovation with affordability etc.<sup id="cite_ref-83" class="reference"><a href="#cite_note-83"><span>[</span>83<span>]</span></a></sup><sup id="cite_ref-84" class="reference"><a href="#cite_note-84"><span>[</span>84<span>]</span></a></sup><sup id="cite_ref-85" class="reference"><a href="#cite_note-85"><span>[</span>85<span>]</span></a></sup></p>
<p>Had Novartis won and gotten its patent issued, it could not have prevented generics companies in India from continuing to sell generic Gleevec, but it could have obligated them to pay a reasonable royalty under a grandfather clause included in India's patent law.<sup id="cite_ref-86" class="reference"><a href="#cite_note-86"><span>[</span>86<span>]</span></a></sup><sup id="cite_ref-87" class="reference"><a href="#cite_note-87"><span>[</span>87<span>]</span></a></sup></p>
<p>In reaction to the decision, Ranjit Shahani, vice-chairman and managing director of Novartis India Ltd was quoted as saying "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options."<sup id="cite_ref-88" class="reference"><a href="#cite_note-88"><span>[</span>88<span>]</span></a></sup> He also said that companies like Novartis would invest less money in research in India as a result of the ruling.<sup id="cite_ref-NYTreact_67-1" class="reference"><a href="#cite_note-NYTreact-67"><span>[</span>67<span>]</span></a></sup> Novartis also emphasized that it continues to be committed to access to its drugs; according to Novartis, by 2013, "95% of patients in India—roughly 16,000 people—receive Glivec free of charge... and it has provided more than $1.7 billion worth of Glivec to Indian patients in its support program since it was started...."<sup id="cite_ref-WSJ_77-1" class="reference"><a href="#cite_note-WSJ-77"><span>[</span>77<span>]</span></a></sup></p>
<h3><span class="mw-headline" id=".22No.22_to_free_flu_vaccines">"No" to free flu vaccines</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=18" title="Edit section: &quot;No&quot; to free flu vaccines">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In June 2009, Novartis declined to provide free vaccines to the poor in order to counter a current flu epidemic, saying developing nations or donor nations should cover the costs. <a href="/wiki/Daniel_Vasella" title="Daniel Vasella">Daniel Vasella</a>, Novartis chief executive, told the <i><a href="/wiki/Financial_Times" title="Financial Times">Financial Times</a></i> that he would consider offering discounted pricing to low-income nations, but unlike <a href="/wiki/GlaxoSmithKline" title="GlaxoSmithKline">GlaxoSmithKline</a>, would not offer vaccines for free.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89"><span>[</span>89<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Sexual_discrimination_class_action_from_5.2C600_current_and_former_employees">Sexual discrimination class action from 5,600 current and former employees</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=19" title="Edit section: Sexual discrimination class action from 5,600 current and former employees">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>On May 17, 2010, a jury in the United States District Court for the Southern District of New York awarded $3,367,250 in <a href="/wiki/Compensatory_damages" title="Compensatory damages" class="mw-redirect">compensatory damages</a> against Novartis, finding that the company had committed <a href="/wiki/Sexual_discrimination" title="Sexual discrimination" class="mw-redirect">sexual discrimination</a> against twelve female <a href="/wiki/Sales_representative" title="Sales representative" class="mw-redirect">sales representatives</a> and entry-level <a href="/wiki/Management" title="Management">managers</a> since 2002, in matters of pay, promotion, and treatment after learning that the employees were <a href="/wiki/Pregnancy" title="Pregnancy">pregnant</a>. Two days later (the trial was bifurcated so that the punitive damages verdict was argued and deliberated separately), the jury awarded <a href="/wiki/Punitive_damages" title="Punitive damages">punitive damages</a> in the amount of $250 million, representing about 2% of Novartis' gross revenues for 2009. Normally punitive damages would be reduced to less than a 10:1 ratio, but the trial was for a group of named plaintiffs in a <a href="/wiki/Class_action" title="Class action">class action</a>, who were representing a class of 5,600 class members. The jury was instructed to award compensatory damages just to the named plaintiffs, but to award punitive damages to the <i>entire</i> class. Once the court makes findings on compensatory damages for the remaining class members (which are estimated by plaintiffs' counsel at just under $1 billion), the $250 million is expected to satisfy the Supreme Court's single-digit ratio test for proportionality of compensatory to punitive damages.<sup id="cite_ref-hamblett2010_90-0" class="reference"><a href="#cite_note-hamblett2010-90"><span>[</span>90<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Off-label_marketing_and_other_marketing_violations">Off-label marketing and other marketing violations</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=20" title="Edit section: Off-label marketing and other marketing violations">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In September 2008, the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">U.S. Food and Drug Administration</a> (FDA) sent a notice to Novartis Pharmaceuticals regarding its advertising of <a href="/wiki/Focalin" title="Focalin" class="mw-redirect">Focalin</a> XR, an <a href="/wiki/ADHD" title="ADHD" class="mw-redirect">ADHD</a> drug, in which the company overstated its efficacy while marketing to the public and medical professionals.<sup id="cite_ref-91" class="reference"><a href="#cite_note-91"><span>[</span>91<span>]</span></a></sup></p>
<p>In 2005 federal prosecutors opened an investigation into Novartis' marketing of several drugs: <a href="/wiki/Trileptal" title="Trileptal" class="mw-redirect">Trileptal</a>, an antiseizure drug; three drugs for heart conditions - <a href="/wiki/Diovan" title="Diovan" class="mw-redirect">Diovan</a> (the company’s top-selling product), <a href="/wiki/Exforge" title="Exforge" class="mw-redirect">Exforge</a>, and <a href="/wiki/Tekturna" title="Tekturna" class="mw-redirect">Tekturna</a>; <a href="/wiki/Sandostatin" title="Sandostatin" class="mw-redirect">Sandostatin</a>, a drug to treat a growth hormone disorder; and <a href="/wiki/Zelnorm" title="Zelnorm" class="mw-redirect">Zelnorm</a>, a drug for irritable bowel syndrome.<sup id="cite_ref-NYTtrileptal_92-0" class="reference"><a href="#cite_note-NYTtrileptal-92"><span>[</span>92<span>]</span></a></sup> In September, 2010, Novartis agreed to pay US$422.5 million in criminal and civil claims and to enter into a Corporate Integrity Agreement with the US Office of the Inspector General.<sup id="cite_ref-93" class="reference"><a href="#cite_note-93"><span>[</span>93<span>]</span></a></sup> According to the New York Times "Federal prosecutors accused Novartis of paying illegal kickbacks to health care professionals through speaker programs, advisory boards, entertainment, travel and meals. But aside from pleading guilty to one misdemeanor charge of mislabeling in an agreement that Novartis announced in February, the company denied wrongdoing."<sup id="cite_ref-NYTtrileptal_92-1" class="reference"><a href="#cite_note-NYTtrileptal-92"><span>[</span>92<span>]</span></a></sup> In the same New York Times article, Frank Lichtenberg, a Columbia professor who receives pharmaceutical financing for research on innovation in the industry, said off-label prescribing was encouraged by the American Medical Association and paid for by insurers, but <a href="/wiki/Off-label_use" title="Off-label use">off-label marketing</a> was clearly illegal. “So it’s not surprising that they would settle because they don’t have a legal leg to stand on."</p>
<p>In April 2013, federal prosecutors filed two lawsuits against Novartis under the <a href="/wiki/False_Claims_Act" title="False Claims Act">False Claims Act</a> for off-label marketing and kickbacks; in both suits, prosecutors are seeking <a href="/wiki/Treble_damages" title="Treble damages">treble damages</a>.<sup id="cite_ref-NYTapril2013_94-0" class="reference"><a href="#cite_note-NYTapril2013-94"><span>[</span>94<span>]</span></a></sup><sup id="cite_ref-DOJ2013_95-0" class="reference"><a href="#cite_note-DOJ2013-95"><span>[</span>95<span>]</span></a></sup> The first suit "accused Novartis of inducing pharmacies to switch thousands of kidney transplant patients to its immunosuppressant drug Myfortic in exchange for kickbacks disguised as rebates and discounts".<sup id="cite_ref-NYTapril2013_94-1" class="reference"><a href="#cite_note-NYTapril2013-94"><span>[</span>94<span>]</span></a></sup> In the second, the Justice Department joined a <i><a href="/wiki/Qui_tam" title="Qui tam">qui tam</a></i>, or whistleblower, lawsuit brought by a former sales rep over off-label marketing of three drugs: <a href="/wiki/Lotrel" title="Lotrel" class="mw-redirect">Lotrel</a> and <a href="/w/index.php?title=Valturna&amp;action=edit&amp;redlink=1" class="new" title="Valturna (page does not exist)">Valturna</a> (both <a href="/wiki/Hypertension" title="Hypertension">hypertension</a> drugs), and the diabetes drug, <a href="/wiki/Starlix" title="Starlix" class="mw-redirect">Starlix</a>.<sup id="cite_ref-DOJ2013_95-1" class="reference"><a href="#cite_note-DOJ2013-95"><span>[</span>95<span>]</span></a></sup> Twenty-seven states, the District of Columbia and Chicago and New York also joined.<sup id="cite_ref-NYTapril2013_94-2" class="reference"><a href="#cite_note-NYTapril2013-94"><span>[</span>94<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Fighting_off-label_prescribing_of_competitor.27s_drug">Fighting off-label prescribing of competitor's drug</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=21" title="Edit section: Fighting off-label prescribing of competitor's drug">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Outside the US, Novartis markets the drug <a href="/wiki/Ranibizumab" title="Ranibizumab">ranibizumab</a> (trade name Lucentis), which is a <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> fragment derived from the same parent mouse antibody as <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a> (Avastin). Both Avastin and Lucentis were created by <a href="/wiki/Genentech" title="Genentech">Genentech</a> which is owned by Roche; Roche markets Avastin worldwide, and also markets Lucentis in the US. Lucentis has been approved worldwide as a treatment for wet <a href="/wiki/Macular_degeneration" title="Macular degeneration">macular degeneration</a> and other retinal disorders; Avastin is used to treat certain cancers. Because the price of Lucentis is much higher than Avastin, many ophthalmologists began having <a href="/wiki/Compounding_pharmacies" title="Compounding pharmacies" class="mw-redirect">compounding pharmacies</a> formulate Avastin for administration to the eye, and began treating their patients with Avastin.<sup id="cite_ref-96" class="reference"><a href="#cite_note-96"><span>[</span>96<span>]</span></a></sup> In 2011, four trusts of the <a href="/wiki/National_Health_Service" title="National Health Service">National Health Service</a> in the UK issued policies approving use and payment for administering Avastin for macular degeneration, in order to save money, even though Avastin had not been approved for that indication.<sup id="cite_ref-BBClucentis_97-0" class="reference"><a href="#cite_note-BBClucentis-97"><span>[</span>97<span>]</span></a></sup> In April 2012, after failing to persuade the trusts that it was uncertain whether Avastin was as safe and effective as Lucentis, and in order to retain the market for Lucentis, Novartis announced it would sue the trusts.<sup id="cite_ref-BBClucentis_97-1" class="reference"><a href="#cite_note-BBClucentis-97"><span>[</span>97<span>]</span></a></sup><sup id="cite_ref-copleyreuters2012_98-0" class="reference"><a href="#cite_note-copleyreuters2012-98"><span>[</span>98<span>]</span></a></sup> However, in July Novartis offered significant discounts (kept confidential) to the trusts, and the trusts agreed to change their policy,<sup id="cite_ref-99" class="reference"><a href="#cite_note-99"><span>[</span>99<span>]</span></a></sup> and in November, Novartis dropped the litigation.<sup id="cite_ref-100" class="reference"><a href="#cite_note-100"><span>[</span>100<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Valsartan_data_scandal_in_Japan">Valsartan data scandal in Japan</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=22" title="Edit section: Valsartan data scandal in Japan">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In the summer of 2013, two Japanese universities retracted several publications of clinical trials that purported to show that <a href="/wiki/Valsartan" title="Valsartan">Valsartan</a> (branded as Diovan) had cardiovascular benefits, when it was found that statistical analysis had been manipulated, and that a Novartis employee had participated in the statistical analysis but had not disclosed his relationship with Novartis but only his affiliation with Osaka City University, where he was a lecturer.<sup id="cite_ref-WSJaug_101-0" class="reference"><a href="#cite_note-WSJaug-101"><span>[</span>101<span>]</span></a></sup> <sup id="cite_ref-102" class="reference"><a href="#cite_note-102"><span>[</span>102<span>]</span></a></sup> The scandal led to several Japanese hospitals to stop using the drug and media outlets to run reports on the scandal and issues with the pharmaceutical industry in Japan.<sup id="cite_ref-WSJaug_101-1" class="reference"><a href="#cite_note-WSJaug-101"><span>[</span>101<span>]</span></a></sup> In January 2014 Japan's Health Ministry filed a criminal complaint with the <a href="/wiki/Tokyo" title="Tokyo">Tokyo</a> public prosecutor's office against Novartis and an unspecified number of employees, for allegedly misleading consumers through advertisements that used the research to support the benefits of Diovan.<sup id="cite_ref-103" class="reference"><a href="#cite_note-103"><span>[</span>103<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=23" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/List_of_pharmaceutical_companies" title="List of pharmaceutical companies">List of pharmaceutical companies</a></li>
<li><a href="/wiki/Pharmaceutical_industry_in_Switzerland" title="Pharmaceutical industry in Switzerland">Pharmaceutical industry in Switzerland</a></li>
</ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=24" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-AR2010-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-AR2010_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-AR2010_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-AR2010_1-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-AR2010_1-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-AR2010_1-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-AR2010_1-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.novartis.com/downloads/investors/reports/novartis-annual-report-2010-en.pdf">"Annual Report 2010"</a> (PDF). Novartis<span class="reference-accessdate">. Retrieved 27 January 2011</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Annual+Report+2010&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.novartis.com%2Fdownloads%2Finvestors%2Freports%2Fnovartis-annual-report-2010-en.pdf&amp;rft.pub=Novartis&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-line%20Market%20Data/2010%20Top-line%20Market%20Data/Top_20_Global_Companies.pdf">"Top 20 global corporations"</a>. IMS<span class="reference-accessdate">. Retrieved 2012-01-06</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Top+20+global+corporations&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.imshealth.com%2Fdeployedfiles%2Fims%2FGlobal%2FContent%2FCorporate%2FPress%2520Room%2FTop-line%2520Market%2520Data%2F2010%2520Top-line%2520Market%2520Data%2FTop_20_Global_Companies.pdf&amp;rft.pub=IMS&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://www.efpia.eu/content/default.asp?PageID=559&amp;DocID=4883">"The Pharmaceutical Industry in Figures - 2008 Edition"</a> (PDF). European Federation of Pharmaceutical Industries and Associations (EFPIA). p.&#160;49<span class="reference-accessdate">. Retrieved 2008-08-25</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=The+Pharmaceutical+Industry+in+Figures+-+2008+Edition&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.efpia.eu%2Fcontent%2Fdefault.asp%3FPageID%3D559%26DocID%3D4883&amp;rft.pages=49&amp;rft.pub=European+Federation+of+Pharmaceutical+Industries+and+Associations+%28EFPIA%29&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.ifpma.org/about-ifpma/members/companies.html">IFPMA Member List</a></span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.phrma.org/about/member-companies">PhRMA Member List</a></span></li>
<li id="cite_note-AR2012-6"><span class="mw-cite-backlink">^ <a href="#cite_ref-AR2012_6-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-AR2012_6-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-AR2012_6-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-AR2012_6-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-AR2012_6-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.novartis.com/downloads/investors/reports/novartis-annual-report-2012-en.pdf">2012 Novartis Group Annual Report</a></span></li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text">Staff, EP Vantage. April 25, 2012 <a rel="nofollow" class="external text" href="http://www.evaluategroup.com/Universal/View.aspx?type=Story&amp;id=292308&amp;isEPVantage=yes">Novartis on track to become world's biggest drug maker</a></span></li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text">Carolyn Gauntlett and Sarah Rickwood for IMS Health. 2013. <a rel="nofollow" class="external text" href="http://www.imshealth.com/deployedfiles/ims/Global/Asia%20Pacific/Content/Insights/Top10%20Pharma%20Companies%20WP%20final_for%20clients.pdf">The changing face of the top 10 pharmaceutical companies</a></span></li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text">Melly Alazraki for Daily Finance. August 26th 2010 <a rel="nofollow" class="external text" href="http://www.dailyfinance.com/2010/08/26/novartis-alcon-buy-majority-stake-nestle/">Novartis Completes Purchase of Alcon Majority Stake from Nestle</a></span></li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text">Staff, Generics Bulletin. June 7, 2013 <a rel="nofollow" class="external text" href="http://www.generics-bulletin.com/media/17399/gennovartisart.pdf">Novartis difference puts Sandoz in prime position</a></span></li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text">Reuters, October 21, 2010 <a rel="nofollow" class="external text" href="http://uk.reuters.com/article/2010/10/21/novartis-biosimilars-idUKLDE69K10V20101021?pageNumber=1">Biosimilars take off at Novartis generics unit</a></span></li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text">Staff, Generics and Biosimilars Initiative, November 9, 2012 <a rel="nofollow" class="external text" href="http://www.gabionline.net/Biosimilars/Research/Sandoz-starts-phase-III-US-trial-for-biosimilar-epoetin-alfa">Sandoz starts phase III US trial for biosimilar epoetin alfa</a></span></li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text">Eric Palmer for FiercePharma, October 11, 2013 <a rel="nofollow" class="external text" href="http://www.fiercepharma.com/story/novartis-whacks-vaccine-jobs-it-eyes-unit-disposal/2013-10-11#ixzz2iCdt46qQ">Novartis whacks vaccine jobs as it eyes unit for disposal</a></span></li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text">Staff and wire reports for the Journal Star (LIncoln, Nebraska) August 14, 2013 <a rel="nofollow" class="external text" href="http://journalstar.com/ap/business/novartis-reviews-business-analyst-urges-selling-otc-unit/article_535693f2-0a29-5cef-9804-f4100c174f41.html">Novartis reviews business; analyst urges selling OTC unit</a></span></li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text">Staff, WHO. <a rel="nofollow" class="external text" href="http://apps.who.int/medicinedocs/documents/s19987en/s19987en.pdf">Access to Medicine Index, 2012</a></span></li>
<li id="cite_note-NYTindex-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYTindex_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYTindex_16-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Donald G McNeil Jr for the New York Times. June 28, 2010 <a rel="nofollow" class="external text" href="http://www.nytimes.com/2010/06/29/health/29glob.html?_r=0">The Drug Industry: GlaxoSmithKline, Merck and Novartis Again Rank Highest on Access to Poor</a></span></li>
<li id="cite_note-novhist-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-novhist_17-0">^</a></b></span> <span class="reference-text"><span id="CITEREF" class="citation"><a rel="nofollow" class="external text" href="http://www.novartis.com/about-novartis/company-history/index.shtml">"Company history"</a>, <i>corporate website</i> (Novartis), novartis.com</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Company+history&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.novartis.com%2Fabout-novartis%2Fcompany-history%2Findex.shtml&amp;rft.jtitle=corporate+website&amp;rft.pages=novartis.com&amp;rft.pub=Novartis&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://web.archive.org/web/20100103182548/http://ciba.com/index/cmp-index/cmp-about/cmp-abo-history.htm">"Archive of Ciba, now a part of BASF: History"</a>. Ciba.com. Archived from <a rel="nofollow" class="external text" href="http://ciba.com/index/cmp-index/cmp-about/cmp-abo-history.htm">the original</a> on 2010-01-03<span class="reference-accessdate">. Retrieved 2013-05-27</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Archive+of+Ciba%2C+now+a+part+of+BASF%3A+History&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fciba.com%2Findex%2Fcmp-index%2Fcmp-about%2Fcmp-abo-history.htm&amp;rft.pub=Ciba.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-MinRec-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-MinRec_19-0">^</a></b></span> <span class="reference-text">Staff, The Mineralogical Record Biographical Archive. <a rel="nofollow" class="external text" href="http://www.minrec.org/labels.asp?colid=765">J.R. Geigy (1830-1917)</a></span></li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text">"Textile auxiliaries" are in the class of <a href="/wiki/Specialty_chemicals" title="Specialty chemicals" class="mw-redirect">specialty chemicals</a> and "enable a processing operation in preparation, dyeing, printing, or finishing to be carried out more effectively or which is essential if a given effect is to be obtained. Certain Textile Auxiliaries are also required in order to produce special finishing effects such as wash &amp; wear, water repellence, flame retardancy, aroma finish, anti odour, colour deepening etc." (from <a rel="nofollow" class="external text" href="http://www.niir.org/books/book/isbn-HandbookonTextileAuxiliaries,DyesandDyeIntermediatesTechnology/zb,,16c,a,0,0,a/index.html">Handbook on Textile Auxiliaries, Dyes and Dye Intermediates Technology</a>, by the NPCS Board of Consultants &amp; Engineers. Asia Pacific Business Press Inc., 2009.</span></li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.cibavision.com/about-us/overview.shtml">Ciba Vision "About us" page</a></span></li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><span class="citation news">By JOSEPH F. SULLIVANPublished: February 29, 1992 (1992-02-29). <a rel="nofollow" class="external text" href="http://www.nytimes.com/1992/02/29/nyregion/ciba-to-pay-new-jersey-for-illegal-waste-dumping.html">"Ciba to Pay New Jersey For Illegal Waste Dumping - New York Times"</a>. Nytimes.com<span class="reference-accessdate">. Retrieved 2013-04-29</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.au=By+JOSEPH+F.+SULLIVANPublished%3A+February+29%2C+1992&amp;rft.aulast=By+JOSEPH+F.+SULLIVANPublished%3A+February+29%2C+1992&amp;rft.btitle=Ciba+to+Pay+New+Jersey+For+Illegal+Waste+Dumping+-+New+York+Times&amp;rft.date=1992-02-29&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F1992%2F02%2F29%2Fnyregion%2Fciba-to-pay-new-jersey-for-illegal-waste-dumping.html&amp;rft.pub=Nytimes.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text">Magnus Grimond for The Independent. March 8, 1996 <a rel="nofollow" class="external text" href="http://www.independent.co.uk/news/business/cibageigy-and-sandoz-to-merge-into-pounds-40bn-giant-1340926.html">Ciba-Geigy and Sandoz to merge into pounds 40bn giant</a></span></li>
<li id="cite_note-NYTmerger-24"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYTmerger_24-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYTmerger_24-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Glenn Collins for the New York Times. March 7, 1996 <a rel="nofollow" class="external text" href="http://www.nytimes.com/1996/03/07/us/2-swiss-drug-giants-in-a-surprise-merger-to-be-2d-in-world.html">2 Swiss Drug Giants In a Surprise Merger To Be 2d in World</a></span></li>
<li id="cite_note-Fisher-25"><span class="mw-cite-backlink">^ <a href="#cite_ref-Fisher_25-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Fisher_25-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Lawrence M. Fisher for strategy + business. April 1, 1998 <a rel="nofollow" class="external text" href="http://www.strategy-business.com/article/16383?gko=28081">Post-Merger Integration: How Novartis Became No. 1</a></span></li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><span class="citation web">Monday - Friday,8:30 - 17:00, GMT+1(Central European Time) (2010-12-15). <a rel="nofollow" class="external text" href="http://www.novartis.com/about-novartis/company-history/index.shtml">"Company history"</a>. Novartis.com<span class="reference-accessdate">. Retrieved 2012-01-16</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.aulast=Monday+-+Friday%2C8%3A30+-+17%3A00%2C+GMT%2B1%28Central+European+Time%29&amp;rft.au=Monday+-+Friday%2C8%3A30+-+17%3A00%2C+GMT%2B1%28Central+European+Time%29&amp;rft.btitle=Company+history&amp;rft.date=2010-12-15&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.novartis.com%2Fabout-novartis%2Fcompany-history%2Findex.shtml&amp;rft.pub=Novartis.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.nysun.com/obituaries/albert-hofmann-102-invented-lsd/75591/">"Albert Hofmann, 102, Invented LSD - The New York Sun"</a>. Nysun.com<span class="reference-accessdate">. Retrieved 2013-10-23</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Albert+Hofmann%2C+102%2C+Invented+LSD+-+The+New+York+Sun&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.nysun.com%2Fobituaries%2Falbert-hofmann-102-invented-lsd%2F75591%2F&amp;rft.pub=Nysun.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.google.com/patents/US2438259">US Patent 2,438,259</a></span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.flashback.se/archive/my_problem_child/chapter4.html#2">"Albert Hofmann: LSD - My Problem Child: Use of LSD in Psychiatry"</a>. Flashback.se<span class="reference-accessdate">. Retrieved 2012-01-16</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Albert+Hofmann%3A+LSD+-+My+Problem+Child%3A+Use+of+LSD+in+Psychiatry&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.flashback.se%2Farchive%2Fmy_problem_child%2Fchapter4.html%232&amp;rft.pub=Flashback.se&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://www.time.com/time/magazine/article/0,9171,860898,00.html">"Medicine: Dream Stuff"</a>. <i>Time</i>. June 28, 1954.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Medicine%3A+Dream+Stuff&amp;rft.date=June+28%2C+1954&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.time.com%2Ftime%2Fmagazine%2Farticle%2F0%2C9171%2C860898%2C00.html&amp;rft.jtitle=Time&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text">Anna Bálint: <i>Clariant clareant. The beginnings of a specialty chemicals company</i>, Campus Verlag, Frankfurt am Main/New York 2012, <a href="/wiki/Special:BookSources/9783593393742" class="internal mw-magiclink-isbn">ISBN 978-3-593-39374-2</a>.</span></li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text">Andrew Ross Sorkin for the New York Times. December 03, 1999 <a rel="nofollow" class="external text" href="http://www.nytimes.com/1999/12/03/business/international-business-astrazeneca-and-novartis-to-shed-agricultural-units.html">AstraZeneca and Novartis To Shed Agricultural Units</a> Accessed May 27, 2013</span></li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text">Staff, PRNewsWire. November 13, 2000. <a rel="nofollow" class="external text" href="http://www.thefreelibrary.com/Syngenta+Begins+Trading+on+the+New+York+Stock+Exchange.-a066871612">Syngenta Begins Trading on the New York Stock Exchange</a> Accessed May 27, 2013</span></li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text">Press Release, Novartis. January 21, 2003 <a rel="nofollow" class="external text" href="http://globenewswire.com/news-release/2003/01/21/293429/35737/en/Novartis-to-Unite-Its-Generics-Businesses-Under-One-Single-Global-Brand-Sandoz.html">Novartis to Unite Its Generics Businesses Under One Single Global Brand: Sandoz</a></span></li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text">Emily Church for MarketWatch Feb. 21, 2005 <a rel="nofollow" class="external text" href="http://www.marketwatch.com/story/novartis-buys-hexal-eon-labs-generics-for-829-bln">Novartis in $8.29 billion generics deals: to buy Hexal and its U.S. division Eon Labs</a></span></li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text">Novartis press release. April 19, 2006 <a rel="nofollow" class="external text" href="http://cws.huginonline.com/N/134323/PR/200604/1045686_5_2.html">Novartis acquisition of Chiron approved by Chiron shareholders</a></span></li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text">Staff, Biosimilars News. August 15, 2011 <a rel="nofollow" class="external text" href="http://www.biosimilarnews.com/biosimilars-approved-in-europe">Biosimilars approved in Europe</a></span></li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text">Andrew Martin and Andrew Ross Sorkin for the New York Times. April 13, 2007 <a rel="nofollow" class="external text" href="http://www.nytimes.com/2007/04/13/business/worldbusiness/13gerber-web.html?_r=0">Nestlé Agrees to Buy Gerber From Novartis</a></span></li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.worldpharmanews.com/content/view/1011/1/">Novartis to expand its human vaccines presence in China</a><sup class="noprint Inline-Template"><span style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title="&#160;since January 2011">dead link</span></a></i>]</span></sup></span></li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><span class="citation news">Thomasson, Emma (4 January 2010). <a rel="nofollow" class="external text" href="http://www.reuters.com/article/2010/01/04/us-alcon-idUSTRE6030RK20100104">"Novartis seeks to buy rest of Alcon for $39 billion"</a>. <i><a href="/wiki/Reuters" title="Reuters">Reuters</a></i><span class="reference-accessdate">. Retrieved 4 January 2010</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Novartis+seeks+to+buy+rest+of+Alcon+for+%2439+billion&amp;rft.aufirst=Emma&amp;rft.aulast=Thomasson&amp;rft.au=Thomasson%2C+Emma&amp;rft.date=4+January+2010&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.reuters.com%2Farticle%2F2010%2F01%2F04%2Fus-alcon-idUSTRE6030RK20100104&amp;rft.jtitle=Reuters&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text">Novartis Press Release. April 08, 2011 <a rel="nofollow" class="external text" href="http://www.novartis.com/newsroom/feature-stories/2011/04/stronger-together-1.shtml">Stronger together: Novartis and Alcon creating the global leader in eye care</a></span></li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><span class="citation news">Maclucas, Neil (2011-01-24). <a rel="nofollow" class="external text" href="http://online.wsj.com/news/articles/SB10001424052748703555804576101840588962926">"Novartis to Buy Genoptix for $470 Million"</a>. Health. <i>The Wall Street Journal</i>. <a rel="nofollow" class="external text" href="http://archive.is/08OsQ">Archived</a> from the original on 2014-01-03.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Novartis+to+Buy+Genoptix+for+%24470+Million&amp;rft.aufirst=Neil&amp;rft.aulast=Maclucas&amp;rft.au=Maclucas%2C+Neil&amp;rft.date=2011-01-24&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fonline.wsj.com%2Fnews%2Farticles%2FSB10001424052748703555804576101840588962926&amp;rft.jtitle=The+Wall+Street+Journal&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-APjp2012-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-APjp2012_43-0">^</a></b></span> <span class="reference-text"><span id="CITEREFAssociated_Press2012" class="citation">Associated Press (January 13, 2012), <a rel="nofollow" class="external text" href="http://www.thejakartapost.com/news/2012/01/13/novartis-cut-almost-2000-us-jobs-year.html">"Novartis to cut almost 2,000 US jobs this year"</a>, <i><a href="/wiki/The_Jakarta_Post" title="The Jakarta Post">The Jakarta Post</a></i>, jakartapost.com<span class="reference-accessdate">, retrieved January 15, 2012</span></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Novartis+to+cut+almost+2%2C000+US+jobs+this+year&amp;rft.au=Associated+Press&amp;rft.aulast=Associated+Press&amp;rft.date=January+13%2C+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.thejakartapost.com%2Fnews%2F2012%2F01%2F13%2Fnovartis-cut-almost-2000-us-jobs-year.html&amp;rft.jtitle=The+Jakarta+Post&amp;rft.pages=jakartapost.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><span id="CITEREFReid2012" class="citation">Reid, Katie (January 13, 2012), Hans-Juergen Peters and Mike Nesbit, ed., <a rel="nofollow" class="external text" href="http://www.reuters.com/article/2012/01/13/us-novartis-idUSTRE80C0EB20120113"><i>Novartis cuts 2,000 U.S. jobs after drug setback</i></a>, Reuters, reuters.com<span class="reference-accessdate">, retrieved January 15, 2012</span></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.aufirst=Katie&amp;rft.aulast=Reid&amp;rft.au=Reid%2C+Katie&amp;rft.btitle=Novartis+cuts+2%2C000+U.S.+jobs+after+drug+setback&amp;rft.date=January+13%2C+2012&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.reuters.com%2Farticle%2F2012%2F01%2F13%2Fus-novartis-idUSTRE80C0EB20120113&amp;rft.pages=reuters.com&amp;rft.pub=Reuters&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://dealbook.nytimes.com/2012/05/02/novartis-to-buy-fougera-pharmaceuticals-for-1-5-billion/">"Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion"</a>. <i>The New York Times</i>. May 2, 2012.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Novartis+to+Buy+Fougera+Pharmaceuticals+for+%241.5+Billion&amp;rft.date=May+2%2C+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fdealbook.nytimes.com%2F2012%2F05%2F02%2Fnovartis-to-buy-fougera-pharmaceuticals-for-1-5-billion%2F&amp;rft.jtitle=The+New+York+Times&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text"><span class="citation news">Harris, Gardiner; Thomas, Katie (2013-04-01). <a rel="nofollow" class="external text" href="http://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html?hp">"Top Court in India Rejects Novartis Drug Patent"</a>. New York Times<span class="reference-accessdate">. Retrieved 1 April 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.aufirst=Gardiner&amp;rft.au=Harris%2C+Gardiner&amp;rft.aulast=Harris&amp;rft.au=Thomas%2C+Katie&amp;rft.btitle=Top+Court+in+India+Rejects+Novartis+Drug+Patent&amp;rft.date=2013-04-01&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F2013%2F04%2F02%2Fbusiness%2Fglobal%2Ftop-court-in-india-rejects-novartis-drug-patent.html%3Fhp&amp;rft.pub=New+York+Times&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.indianexpress.com/news/us-sues-novartis-again-says-it-bribed-doctors-for-patents/1108452/">"US sues Novartis again, says it bribed doctors for patents"</a>. Indian Express<span class="reference-accessdate">. Retrieved 2013-04-29</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=US+sues+Novartis+again%2C+says+it+bribed+doctors+for+patents&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.indianexpress.com%2Fnews%2Fus-sues-novartis-again-says-it-bribed-doctors-for-patents%2F1108452%2F&amp;rft.pub=Indian+Express&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><span class="citation web">Tracy Staton (2014-01-21). <a rel="nofollow" class="external text" href="http://www.fiercepharma.com/story/novartis-cut-500-swiss-pharma-jobs-then-staff-otc-generics/2014-01-21">"Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics"</a>. FiercePharma<span class="reference-accessdate">. Retrieved 2014-02-19</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.aulast=Tracy+Staton&amp;rft.au=Tracy+Staton&amp;rft.btitle=Novartis+to+cut+500+Swiss+pharma+jobs%2C+then+staff+up+in+OTC%2C+generics&amp;rft.date=2014-01-21&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.fiercepharma.com%2Fstory%2Fnovartis-cut-500-swiss-pharma-jobs-then-staff-otc-generics%2F2014-01-21&amp;rft.pub=FiercePharma&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://www.drugstorenews.com/article/novartis-acquires-costim-pharmaceuticals">"Novartis acquires CoStim Pharmaceuticals"</a>. <i>Drug Store News</i>. January 18, 2014<span class="reference-accessdate">. Retrieved February 19, 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Novartis+acquires+CoStim+Pharmaceuticals&amp;rft.date=January+18%2C+2014&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.drugstorenews.com%2Farticle%2Fnovartis-acquires-costim-pharmaceuticals&amp;rft.jtitle=Drug+Store+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><span class="citation news">Ross, Casey (2010-10-27). <a rel="nofollow" class="external text" href="http://www.boston.com/business/healthcare/articles/2010/10/27/novartis_doubles_plan_for_cambridge/">"Novartis doubles plan for Cambridge"</a>. <i>Boston Globe</i><span class="reference-accessdate">. Retrieved 2010-10-31</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Novartis+doubles+plan+for+Cambridge&amp;rft.aufirst=Casey&amp;rft.aulast=Ross&amp;rft.au=Ross%2C+Casey&amp;rft.date=2010-10-27&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.boston.com%2Fbusiness%2Fhealthcare%2Farticles%2F2010%2F10%2F27%2Fnovartis_doubles_plan_for_cambridge%2F&amp;rft.jtitle=Boston+Globe&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.nibr.com/">Novartis Institutes for BioMedical Research Official SIte</a></span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.nibr.com/research/developing_world/index.shtml">Innovation for the developing world</a></span></li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><span class="citation book">Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. <i>Essential Concepts in Toxicogenomics</i>. <a href="/wiki/Methods_in_Molecular_Biology" title="Methods in Molecular Biology">Methods in Molecular Biology</a> <b>460</b>. pp.&#160;221–238. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2F978-1-60327-048-9_11">10.1007/978-1-60327-048-9_11</a>. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-1-58829-638-2" title="Special:BookSources/978-1-58829-638-2">978-1-58829-638-2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18449490">18449490</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Essential+Concepts+in+Toxicogenomics&amp;rft.aufirst=William+B.&amp;rft.aulast=Mattes&amp;rft.au=Mattes%2C+William+B.&amp;rft.btitle=Public+Consortium+Efforts+in+Toxicogenomics&amp;rft.date=2008&amp;rft.genre=bookitem&amp;rft_id=info%3Adoi%2F10.1007%2F978-1-60327-048-9_11&amp;rft_id=info%3Apmid%2F18449490&amp;rft.isbn=978-1-58829-638-2&amp;rft.pages=221-238&amp;rft.series=Methods+in+Molecular+Biology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.volume=460" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="plainlinks noprint" style="font-size:smaller"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Cite_doi/10.1007.2F978-1-60327-048-9_11&amp;action=edit&amp;editintro=Template:Cite_doi/editintro2">edit</a></span></span></li>
<li id="cite_note-InnoMed_PredTox_official_project_website-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-InnoMed_PredTox_official_project_website_54-0">^</a></b></span> <span class="reference-text"><span id="CITEREF" class="citation"><a rel="nofollow" class="external text" href="http://web.archive.org/web/20080926214522/http://www.innomed-predtox.com/consortium/members/"><i>InnoMed PredTox Member Organizations</i></a> (web page), InnoMed, archived from <a rel="nofollow" class="external text" href="http://www.innomed-predtox.com/consortium/members/">the original</a> on 2008-09-26<span class="reference-accessdate">, retrieved 2008-08-25</span></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=InnoMed+PredTox+Member+Organizations&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.innomed-predtox.com%2Fconsortium%2Fmembers%2F&amp;rft.pub=InnoMed&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-IMI_Call_Topics_2008-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-IMI_Call_Topics_2008_55-0">^</a></b></span> <span class="reference-text"><span id="CITEREFInnovative_Medicines_Initiative2008" class="citation">Innovative Medicines Initiative, ed. (2008), <a rel="nofollow" class="external text" href="http://www.imi.europa.eu/sites/default/files/uploads/documents/calls01_en.zip">"IMI-GB-018v2-24042008-CallTopics.pdf"</a> (PDF), <i>IMI 1<sup>st</sup> Call 2008: Information Package (ZIP archive)</i> (European Commission)<span class="reference-accessdate">, retrieved 2012-01-16</span></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=IMI-GB-018v2-24042008-CallTopics.pdf&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.imi.europa.eu%2Fsites%2Fdefault%2Ffiles%2Fuploads%2Fdocuments%2Fcalls01_en.zip&amp;rft.jtitle=IMI+1%3Csup%3Est%3C%2Fsup%3E+Call+2008%3A+Information+Package+%28ZIP+archive%29&amp;rft.pub=European+Commission&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-novartis1-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-novartis1_56-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.novartis.com/about-novartis/locations/basel-campus-project.shtml">"Basel Campus Project"</a>. Novartis<span class="reference-accessdate">. Retrieved 2007-10-11</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Basel+Campus+Project&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.novartis.com%2Fabout-novartis%2Flocations%2Fbasel-campus-project.shtml&amp;rft.pub=Novartis&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-2012Sales-57"><span class="mw-cite-backlink">^ <a href="#cite_ref-2012Sales_57-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-2012Sales_57-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-2012Sales_57-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-2012Sales_57-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-2012Sales_57-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-2012Sales_57-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-2012Sales_57-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-2012Sales_57-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-2012Sales_57-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-2012Sales_57-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-2012Sales_57-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-2012Sales_57-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-2012Sales_57-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-2012Sales_57-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-2012Sales_57-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-2012Sales_57-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-2012Sales_57-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-2012Sales_57-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-2012Sales_57-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-2012Sales_57-19"><sup><i><b>t</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.novartis.com/investors/financial-results/product-sales.shtml">Novartis Top 20 Products Annual Sales (Novartis Website)</a>, accessed October 19, 2013</span></li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text">Teva press release. January 30, 2007 <a rel="nofollow" class="external text" href="http://ir.tevapharm.com/phoenix.zhtml?c=73925&amp;p=irol-newsArticle_Print&amp;ID=1554585&amp;highlight=">Teva Receives Approval for Generic Focalin™ Tablets</a></span></li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.pitchengine.com/theproactivenetwork/ipci-fda-approves-first-focalin-xr-anda-positive-incremental-step-toward-approval-and-october-launch-for-ipci">"IPCI: FDA Approves First Focalin XR ANDA; Positive Incremental Step Toward Approval and October Launch for IPCI"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=IPCI%3A+FDA+Approves+First+Focalin+XR+ANDA%3B+Positive+Incremental+Step+Toward+Approval+and+October+Launch+for+IPCI&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.pitchengine.com%2Ftheproactivenetwork%2Fipci-fda-approves-first-focalin-xr-anda-positive-incremental-step-toward-approval-and-october-launch-for-ipci&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-novartis2007sales-60"><span class="mw-cite-backlink">^ <a href="#cite_ref-novartis2007sales_60-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-novartis2007sales_60-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-novartis2007sales_60-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://web.archive.org/web/20071113234423/http://www.novartis.com/investors/product-sales.shtml">Novartis official 2007 product sales</a> From Internet Archive; archive date November 13, 2007</span></li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000677.jsp">EMEA Approval for Pasireotide</a></span></li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.medscape.com/viewarticle/776273">"FDA Approves Pasireotide for Cushing's Disease"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=FDA+Approves+Pasireotide+for+Cushing%27s+Disease&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F776273&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-wsjtasigna2012-63"><span class="mw-cite-backlink">^ <a href="#cite_ref-wsjtasigna2012_63-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-wsjtasigna2012_63-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span id="CITEREF2012" class="citation"><a rel="nofollow" class="external text" href="http://online.wsj.com/article/BT-CO-20120112-715529.html">"NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel"</a>, <i><a href="/wiki/Wall_Street_Journal" title="Wall Street Journal" class="mw-redirect">Wall Street Journal</a></i>, 12 January 2012, online.wsj.com<span class="reference-accessdate">, retrieved 15 Jan 2012</span></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=NICE+Backs+Novartis%27s+Tasigna+For+CML%2C+Rejects+BMS%27s+Sprycel&amp;rft.date=12+January+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fonline.wsj.com%2Farticle%2FBT-CO-20120112-715529.html&amp;rft.jtitle=Wall+Street+Journal&amp;rft.pages=online.wsj.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Teva2013-64"><span class="mw-cite-backlink">^ <a href="#cite_ref-Teva2013_64-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Teva2013_64-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Teva press release. October 14, 2013 <a rel="nofollow" class="external text" href="http://www.ir.tevapharm.com/phoenix.zhtml?c=73925&amp;p=irol-newsArticle&amp;id=1864100">Teva Announces FDA Approval of Generic TOBI® in the United States</a></span></li>
<li id="cite_note-teva2007-65"><span class="mw-cite-backlink">^ <a href="#cite_ref-teva2007_65-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-teva2007_65-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Teva Press Release December 12, 2007 <a rel="nofollow" class="external text" href="http://www.drugs.com/newdrugs/teva-announces-approval-trileptal-736.html">Teva Announces Approval of Generic Trileptal Tablets</a></span></li>
<li id="cite_note-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-66">^</a></b></span> <span class="reference-text"><span class="citation pressrelease"><a rel="nofollow" class="external text" href="http://www.novartis.com/newsroom/media-releases/en/2009/1282432.shtml">"US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine"</a> (Press release). Novartis. January 15, 2009<span class="reference-accessdate">. Retrieved 2009-11-13</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=US+Department+of+Health+and+Human+Services+awards+Novartis+USD+486+million+contract+to+build+manufacturing+facility+for+pandemic+flu+vaccine&amp;rft.date=January+15%2C+2009&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.novartis.com%2Fnewsroom%2Fmedia-releases%2Fen%2F2009%2F1282432.shtml&amp;rft.pub=Novartis&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NYTreact-67"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYTreact_67-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYTreact_67-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Gardiner Harris and Katie Thomas for the New York Times. April 1, 2013 <a rel="nofollow" class="external text" href="http://www.nytimes.com/2013/04/02/business/global/top-court-in-india-rejects-novartis-drug-patent.html?ref=world">Top court in India rejects Novartis drug patent</a></span></li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text">Note: The Indian patent application No.1602/MAS/1998 does not appear to be publicly available. However according to <a rel="nofollow" class="external text" href="http://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India">the decision of the IPAB on 26 June 2009</a> (page 27) discussed below, "The Appellant’s application under the PCT was substantially on the same invention as had been made in India."</span></li>
<li id="cite_note-PCT-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-PCT_69-0">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://patentscope.wipo.int/search/en/detail.jsf?docId=WO1999003854">Published PCT application WO1999003854</a></span></li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text">Staff, European Medicines Agency, 2004. <a rel="nofollow" class="external text" href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000406/WC500022203.pdf">EMEA Scientific Discussion of Glivec</a></span></li>
<li id="cite_note-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-71">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.google.com/patents/US5521184">US Patent 5,521,184</a></span></li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://worldwide.espacenet.com/searchResults?query=EP0564409">EP0564409</a></span></li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212">Indian Supreme Court Decision</a> paragraphs 5-6</span></li>
<li id="cite_note-Decision8-9-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-Decision8-9_74-0">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212">Novartis v UoI, para 8-9</a></span></li>
<li id="cite_note-SpicyIP1-75"><span class="mw-cite-backlink">^ <a href="#cite_ref-SpicyIP1_75-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-SpicyIP1_75-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Shamnad Basheer for Spicy IP March 11, 2006 <a rel="nofollow" class="external text" href="http://spicyip.com/2006/03/first-mailbox-opposition-gleevec.html">First Mailbox Opposition (Gleevec) Decided in India</a></span></li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text">Staff, LawyersCollective. September 6, 2011 <a rel="nofollow" class="external text" href="http://www.lawyerscollective.org/news/archived-news-a-articles/126-novartis-case-background-and-update-supreme-court-of-india-to-recommence-hearing.html">Novartis case: background and update – Supreme Court of India to recommence hearing</a></span></li>
<li id="cite_note-WSJ-77"><span class="mw-cite-backlink">^ <a href="#cite_ref-WSJ_77-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-WSJ_77-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">R. Jai Krishna and Jeanne Whalen for the Wall Street Journal. April 1, 2013 <a rel="nofollow" class="external text" href="http://online.wsj.com/news/articles/SB10001424127887323296504578395672582230106">Novartis Loses Glivec Patent Battle in India</a></span></li>
<li id="cite_note-Appellate-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-Appellate_78-0">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.scribd.com/doc/133340456/IPAB-Order-Dated-26-Jun-2009-in-Novartis-v-Union-of-India">Intellectual Property Appellate Board decision dated 26 June 2009, p 149</a></span></li>
<li id="cite_note-2007Decn-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-2007Decn_79-0">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://judis.nic.in/judis_chennai/qrydispfree.aspx?filename=11121">W.P. No.24759 of 2006</a></span></li>
<li id="cite_note-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-80">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://spicyipindia.blogspot.co.uk/2013/04/supreme-court-rejects-bid-by-novartis.html">"Supreme Court rejects bid by Novartis to patent Glivec"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Supreme+Court+rejects+bid+by+Novartis+to+patent+Glivec&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fspicyipindia.blogspot.co.uk%2F2013%2F04%2Fsupreme-court-rejects-bid-by-novartis.html&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-81">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212">Novartis v UoI, Para 191</a></span></li>
<li id="cite_note-Decision24-82"><span class="mw-cite-backlink"><b><a href="#cite_ref-Decision24_82-0">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212">Novartis v UoI, Para 24-25</a></span></li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.firstpost.com/world/how-the-indian-judgment-on-novartis-will-reverberate-across-the-world-684767.html">"How the Indian judgment will reverberate across the world"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=How+the+Indian+judgment+will+reverberate+across+the+world&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.firstpost.com%2Fworld%2Fhow-the-indian-judgment-on-novartis-will-reverberate-across-the-world-684767.html&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://articles.economictimes.indiatimes.com/2013-04-03/news/38248707_1_patent-protection-glivec-indian-patent-act">"Patented drugs must be priced smartly"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Patented+drugs+must+be+priced+smartly&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Farticles.economictimes.indiatimes.com%2F2013-04-03%2Fnews%2F38248707_1_patent-protection-glivec-indian-patent-act&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-85">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.indianexpress.com/news/patent-with-a-purpose/1096741/0">Patent with a purpose, Prof. Shamnad Basheer, Indian Express, 3 April 2013</a></span></li>
<li id="cite_note-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-86">^</a></b></span> <span class="reference-text">Kevin Grogan for PharmaTimes. February 27, 2012 <a rel="nofollow" class="external text" href="http://www.pharmatimes.com/article/12-02-27/Novartis_explains_stance_over_India_patent_law_challenge.aspx">Novartis explains stance over India patent law challenge</a></span></li>
<li id="cite_note-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-87">^</a></b></span> <span class="reference-text">Berne Declaration. May 8, 2007 <a rel="nofollow" class="external text" href="http://www.evb.ch/en/p25012749.html">Short questions and answers about the court case initiated by Novartis in India</a></span></li>
<li id="cite_note-88"><span class="mw-cite-backlink"><b><a href="#cite_ref-88">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.telegraphindia.com/1130402/jsp/business/story_16736700.jsp#.UV3-TcV49_M">Shift in Novartis Strategy, The Telegraph</a></span></li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.ft.com/cms/s/0/5f358b4e-5944-11de-80b3-00144feabdc0.html?nclick_check=1">"Novartis says 'no' to free flu vaccines"</a>. Andrew Jack. <i><a href="/wiki/Financial_Times" title="Financial Times">Financial Times</a></i>. June 15, 2009.</span></li>
<li id="cite_note-hamblett2010-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-hamblett2010_90-0">^</a></b></span> <span class="reference-text"><span class="citation web">Mark Hamblett (<a href="/wiki/New_York_Law_Journal" title="New York Law Journal">New York Law Journal</a>) (2010-05-20). <a rel="nofollow" class="external text" href="http://www.law.com/jsp/article.jsp?id=1202458479079">"Novartis Hit With $250 Million in Punitives in Gender Bias Case"</a>. <i>law.com</i>. <a href="/w/index.php?title=ALM_Media&amp;action=edit&amp;redlink=1" class="new" title="ALM Media (page does not exist)">ALM Media</a><span class="reference-accessdate">. Retrieved 2012-01-16</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Novartis+Hit+With+%24250+Million+in+Punitives+in+Gender+Bias+Case&amp;rft.aulast=Mark+Hamblett+%28New+York+Law+Journal%29&amp;rft.au=Mark+Hamblett+%28New+York+Law+Journal%29&amp;rft.date=2010-05-20&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.law.com%2Fjsp%2Farticle.jsp%3Fid%3D1202458479079&amp;rft.jtitle=law.com&amp;rft.pub=ALM+Media&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-91"><span class="mw-cite-backlink"><b><a href="#cite_ref-91">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048118.htm">"Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules CII"</a>. <i>Warning Letters</i>. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">U.S. Food and Drug Administration</a> (FDA). 2008-09-25<span class="reference-accessdate">. Retrieved 2009-08-05</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.atitle=Focalin+XR+%28dexmethylphenidate+hydrochloride%29+extended-release+capsules+CII&amp;rft.date=2008-09-25&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FICECI%2FEnforcementActions%2FWarningLetters%2F2008%2Fucm1048118.htm&amp;rft.jtitle=Warning+Letters&amp;rft.pub=U.S.+Food+and+Drug+Administration+%28FDA%29&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NYTtrileptal-92"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYTtrileptal_92-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYTtrileptal_92-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation news">Wilson, Duff (2010-09-30). <a rel="nofollow" class="external text" href="http://www.nytimes.com/2010/10/01/health/policy/01novartis.html">"Novartis Settles Off-Label Marketing Case"</a>. NYTimes.com<span class="reference-accessdate">. Retrieved 2012-01-16</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.aufirst=Duff&amp;rft.aulast=Wilson&amp;rft.au=Wilson%2C+Duff&amp;rft.btitle=Novartis+Settles+Off-Label+Marketing+Case&amp;rft.date=2010-09-30&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F2010%2F10%2F01%2Fhealth%2Fpolicy%2F01novartis.html&amp;rft.pub=NYTimes.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-93"><span class="mw-cite-backlink"><b><a href="#cite_ref-93">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.novartis.com/newsroom/media-releases/en/2010/1448151.shtml">"Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office"</a> (press release). Novartis. 2010-09-30. Media Releases<span class="reference-accessdate">. Retrieved 2012-01-16</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Novartis+Pharmaceuticals+Corporation%2C+a+US+subsidiary+of+Novartis+AG%2C+reaches+settlement+agreement+with+US+Attorney%27s+Office&amp;rft.date=2010-09-30&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.novartis.com%2Fnewsroom%2Fmedia-releases%2Fen%2F2010%2F1448151.shtml&amp;rft.pages=Media+Releases&amp;rft.pub=Novartis&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NYTapril2013-94"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYTapril2013_94-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYTapril2013_94-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NYTapril2013_94-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://www.nytimes.com/2013/04/27/business/us-files-2nd-suit-accusing-novartis-of-kickbacks-to-doctors.html?_r=0">"U.S. Sues Novartis Again, Accusing It of Kickbacks"</a>. New York Times. 2013-04-26<span class="reference-accessdate">. Retrieved 2013-04-27</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=U.S.+Sues+Novartis+Again%2C+Accusing+It+of+Kickbacks&amp;rft.date=2013-04-26&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F2013%2F04%2F27%2Fbusiness%2Fus-files-2nd-suit-accusing-novartis-of-kickbacks-to-doctors.html%3F_r%3D0&amp;rft.pub=New+York+Times&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DOJ2013-95"><span class="mw-cite-backlink">^ <a href="#cite_ref-DOJ2013_95-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-DOJ2013_95-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.justice.gov/opa/pr/2013/April/13-civ-481.html">"United States Files Complaint Against Novartis Pharmaceuticals Corp. for Allegedly Paying Kickbacks to Doctors in Exchange for Prescribing Its Drugs"</a>. The United States Department of Justice. 2013-04-26<span class="reference-accessdate">. Retrieved 2013-04-26</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=United+States+Files+Complaint+Against+Novartis+Pharmaceuticals+Corp.+for+Allegedly+Paying+Kickbacks+to+Doctors+in+Exchange+for+Prescribing+Its+Drugs&amp;rft.date=2013-04-26&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.justice.gov%2Fopa%2Fpr%2F2013%2FApril%2F13-civ-481.html&amp;rft.pub=The+United+States+Department+of+Justice&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-96">^</a></b></span> <span class="reference-text">Andrew Pollack for the New York Times. April 28, 2011 <a rel="nofollow" class="external text" href="http://www.nytimes.com/2011/04/29/business/29eye.html?_r=0">Cheaper Drug to Treat Eye Disease Is Effective</a></span></li>
<li id="cite_note-BBClucentis-97"><span class="mw-cite-backlink">^ <a href="#cite_ref-BBClucentis_97-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-BBClucentis_97-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation news">Jeffreys, Branwen (2012-05-06). <a rel="nofollow" class="external text" href="http://www.bbc.co.uk/news/health-17956425">"Using Avastin for eye condition wet AMD 'could save NHS £84m<span style="padding-right:0.2em;">'</span>"</a>. bbc.com<span class="reference-accessdate">. Retrieved 2012-05-06</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.aufirst=Branwen&amp;rft.au=Jeffreys%2C+Branwen&amp;rft.aulast=Jeffreys&amp;rft.btitle=Using+Avastin+for+eye+condition+wet+AMD+%27could+save+NHS+%C2%A384m%27&amp;rft.date=2012-05-06&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.bbc.co.uk%2Fnews%2Fhealth-17956425&amp;rft.pub=bbc.com&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-copleyreuters2012-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-copleyreuters2012_98-0">^</a></b></span> <span class="reference-text"><span id="CITEREFCopleyHirschler2012" class="citation">Copley, Caroline; Hirschler, Ben (April 24, 2012), Potter, Mark, ed., <a rel="nofollow" class="external text" href="http://www.reuters.com/article/2012/04/24/us-novartis-britain-idUSBRE83N0GM20120424"><i>Novartis challenges UK Avastin use in eye disease</i></a>, Reuters<span class="reference-accessdate">, retrieved April 29, 2012</span></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.au=Copley%2C+Caroline&amp;rft.aufirst=Caroline&amp;rft.au=Hirschler%2C+Ben&amp;rft.aulast=Copley&amp;rft.btitle=Novartis+challenges+UK+Avastin+use+in+eye+disease&amp;rft.date=April+24%2C+2012&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.reuters.com%2Farticle%2F2012%2F04%2F24%2Fus-novartis-britain-idUSBRE83N0GM20120424&amp;rft.pub=Reuters&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-99">^</a></b></span> <span class="reference-text">Ben Adams for Pharmafile. July 26, 2012 <a rel="nofollow" class="external text" href="http://www.pharmafile.com/news/173606/lucentis-price-cut-ends-pct-novartis-dispute">Lucentis price cut ends PCT-Novartis dispute</a></span></li>
<li id="cite_note-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-100">^</a></b></span> <span class="reference-text">Ben Adams for Pharma Times. October 3, 2012. <a rel="nofollow" class="external text" href="http://www.pharmatimes.com/Article/12-10-03/Novartis_to_drop_legal_case_against_NHS_body.aspx">Novartis to drop legal case against NHS body</a></span></li>
<li id="cite_note-WSJaug-101"><span class="mw-cite-backlink">^ <a href="#cite_ref-WSJaug_101-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-WSJaug_101-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Kana Inagaki for the Wall Street Journal. Aug. 11, 2013 <a rel="nofollow" class="external text" href="http://online.wsj.com/news/articles/SB10001424127887323838204579000403952581982">Novartis Hit by Scandal Over Japanese Drug Studies: Probes Uncover Altered Research Data; Swiss Giant Stands by Heart Medicine Diovan</a></span></li>
<li id="cite_note-102"><span class="mw-cite-backlink"><b><a href="#cite_ref-102">^</a></b></span> <span class="reference-text">Kana Inagaki for the Wall Street Journal. August 12, 2013. <a rel="nofollow" class="external text" href="http://blogs.wsj.com/japanrealtime/2013/08/12/novartis-drug-studies-in-japan-tracing-back-the-questions/">Novartis Drug Studies in Japan–Tracing Back the Questions</a></span></li>
<li id="cite_note-103"><span class="mw-cite-backlink"><b><a href="#cite_ref-103">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://online.wsj.com/news/articles/SB10001424052702303933104579307443220022558">"Japan Criminal Probe Could Spell More Trouble for Novartis"</a>. Wall Street Journal. January 10, 2014.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ANovartis&amp;rft.btitle=Japan+Criminal+Probe+Could+Spell+More+Trouble+for+Novartis&amp;rft.date=January+10%2C+2014&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fonline.wsj.com%2Fnews%2Farticles%2FSB10001424052702303933104579307443220022558&amp;rft.pub=Wall+Street+Journal&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Novartis&amp;action=edit&amp;section=25" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table class="metadata mbox-small plainlinks" style="border:1px solid #aaa; background-color:#f9f9f9;">
<tr>
<td class="mbox-image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/30px-Commons-logo.svg.png" width="30" height="40" srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/45px-Commons-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/59px-Commons-logo.svg.png 2x" /></td>
<td class="mbox-text plainlist" style="">Wikimedia Commons has media related to <i><b><a href="//commons.wikimedia.org/wiki/Category:Novartis" class="extiw" title="commons:Category:Novartis">Novartis</a></b></i>.</td>
</tr>
</table>
<ul>
<li><span class="official website"><span class="url"><a rel="nofollow" class="external text" href="http://www.novartis.com/">Official website</a></span></span></li>
</ul>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Swiss_Market_Index_companies" title="Template:Swiss Market Index companies"><span title="View this template" style=";;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Swiss_Market_Index_companies" title="Template talk:Swiss Market Index companies"><span title="Discuss this template" style=";;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Swiss_Market_Index_companies&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><span class="flagicon"><a href="/wiki/Switzerland" title="Switzerland"><img alt="Switzerland" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Flag_of_Switzerland.svg/16px-Flag_of_Switzerland.svg.png" width="16" height="16" class="thumbborder" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Flag_of_Switzerland.svg/24px-Flag_of_Switzerland.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Flag_of_Switzerland.svg/32px-Flag_of_Switzerland.svg.png 2x" /></a></span> <a href="/wiki/Swiss_Market_Index" title="Swiss Market Index">Swiss Market Index</a> companies of Switzerland</div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/ABB_Group" title="ABB Group">ABB</a></li>
<li><a href="/wiki/Actelion" title="Actelion">Actelion</a></li>
<li><a href="/wiki/Adecco" title="Adecco">Adecco</a></li>
<li><a href="/wiki/Credit_Suisse" title="Credit Suisse">Credit Suisse</a></li>
<li><a href="/wiki/Geberit" title="Geberit">Geberit</a></li>
<li><a href="/wiki/Givaudan" title="Givaudan">Givaudan</a></li>
<li><a href="/wiki/Holcim" title="Holcim">Holcim</a></li>
<li><a href="/wiki/Julius_Baer_Group" title="Julius Baer Group">Julius Bär</a></li>
<li><a href="/wiki/Nestl%C3%A9" title="Nestlé">Nestlé</a></li>
<li><strong class="selflink">Novartis</strong></li>
<li><a href="/wiki/Richemont" title="Richemont">Richemont</a></li>
<li><a href="/wiki/Hoffmann-La_Roche" title="Hoffmann-La Roche">Roche</a></li>
<li><a href="/wiki/SGS_S.A." title="SGS S.A.">SGS</a></li>
<li><a href="/wiki/The_Swatch_Group" title="The Swatch Group">Swatch Group</a></li>
<li><a href="/wiki/Swiss_Re" title="Swiss Re">Swiss Re</a></li>
<li><a href="/wiki/Swisscom" title="Swisscom">Swisscom</a></li>
<li><a href="/wiki/Syngenta" title="Syngenta">Syngenta</a></li>
<li><a href="/wiki/Transocean" title="Transocean">Transocean</a></li>
<li><a href="/wiki/UBS" title="UBS">UBS</a></li>
<li><a href="/wiki/Zurich_Financial_Services" title="Zurich Financial Services" class="mw-redirect">Zurich Financial</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks noprint navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li style="display:inline;white-space:nowrap;"><span style="margin:auto 0.5em;"><a href="/wiki/File:Factory_1b.svg" class="image"><img alt="Factory 1b.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b6/Factory_1b.svg/24px-Factory_1b.svg.png" width="24" height="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b6/Factory_1b.svg/36px-Factory_1b.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b6/Factory_1b.svg/48px-Factory_1b.svg.png 2x" /></a></span><span style="font-weight:bold;"><a href="/wiki/Portal:Companies" title="Portal:Companies">Companies portal</a></span></li>
<li style="display:inline;white-space:nowrap;"><span style="margin:auto 0.5em;"><a href="/wiki/File:Flag_of_Switzerland.svg" class="image"><img alt="Flag of Switzerland.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Flag_of_Switzerland.svg/21px-Flag_of_Switzerland.svg.png" width="21" height="21" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Flag_of_Switzerland.svg/32px-Flag_of_Switzerland.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Flag_of_Switzerland.svg/42px-Flag_of_Switzerland.svg.png 2x" /></a></span><span style="font-weight:bold;"><a href="/wiki/Portal:Switzerland" title="Portal:Switzerland">Switzerland portal</a></span></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1216
CPU time usage: 2.368 seconds
Real time usage: 2.534 seconds
Preprocessor visited node count: 7853/1000000
Preprocessor generated node count: 29792/1500000
Post‐expand include size: 110963/2048000 bytes
Template argument size: 6564/2048000 bytes
Highest expansion depth: 13/40
Expensive parser function count: 6/500
Lua time usage: 0.176/10.000 seconds
Lua memory usage: 3.31 MB/50 MB
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:159284-0!*!0!!en!4!* and timestamp 20140410022315
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>								<div class="printfooter">
				Retrieved from "<a href="http://en.wikipedia.org/w/index.php?title=Novartis&amp;oldid=602624408">http://en.wikipedia.org/w/index.php?title=Novartis&amp;oldid=602624408</a>"				</div>
												<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Companies_listed_on_the_New_York_Stock_Exchange" title="Category:Companies listed on the New York Stock Exchange">Companies listed on the New York Stock Exchange</a></li><li><a href="/wiki/Category:Biotechnology_companies" title="Category:Biotechnology companies">Biotechnology companies</a></li><li><a href="/wiki/Category:Multinational_companies_headquartered_in_Switzerland" title="Category:Multinational companies headquartered in Switzerland">Multinational companies headquartered in Switzerland</a></li><li><a href="/wiki/Category:Novartis" title="Category:Novartis">Novartis</a></li><li><a href="/wiki/Category:Pharmaceutical_companies_of_Switzerland" title="Category:Pharmaceutical companies of Switzerland">Pharmaceutical companies of Switzerland</a></li><li><a href="/wiki/Category:Vaccine_producers" title="Category:Vaccine producers">Vaccine producers</a></li><li><a href="/wiki/Category:Veterinary_medicine_companies" title="Category:Veterinary medicine companies">Veterinary medicine companies</a></li><li><a href="/wiki/Category:Companies_established_in_1996" title="Category:Companies established in 1996">Companies established in 1996</a></li><li><a href="/wiki/Category:Companies_based_in_Basel" title="Category:Companies based in Basel">Companies based in Basel</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:All_articles_with_dead_external_links" title="Category:All articles with dead external links">All articles with dead external links</a></li><li><a href="/wiki/Category:Articles_with_dead_external_links_from_January_2011" title="Category:Articles with dead external links from January 2011">Articles with dead external links from January 2011</a></li><li><a href="/wiki/Category:Articles_containing_potentially_dated_statements_from_2013" title="Category:Articles containing potentially dated statements from 2013">Articles containing potentially dated statements from 2013</a></li><li><a href="/wiki/Category:All_articles_containing_potentially_dated_statements" title="Category:All articles containing potentially dated statements">All articles containing potentially dated statements</a></li><li><a href="/wiki/Category:Commons_category_with_local_link_same_as_on_Wikidata" title="Category:Commons category with local link same as on Wikidata">Commons category with local link same as on Wikidata</a></li></ul></div></div>												<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>
			<div id="mw-head">
				<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
	<h3 id="p-personal-label">Personal tools</h3>
	<ul>
<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Novartis&amp;type=signup">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Novartis" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>	</ul>
</div>
				<div id="left-navigation">
					<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
	<h3 id="p-namespaces-label">Namespaces</h3>
	<ul>
					<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Novartis"  title="View the content page [c]" accesskey="c">Article</a></span></li>
					<li  id="ca-talk"><span><a href="/wiki/Talk:Novartis"  title="Discussion about the content page [t]" accesskey="t">Talk</a></span></li>
			</ul>
</div>
<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
	<h3 id="mw-vector-current-variant">
		</h3>
	<h3 id="p-variants-label"><span>Variants</span><a href="#"></a></h3>
	<div class="menu">
		<ul>
					</ul>
	</div>
</div>
				</div>
				<div id="right-navigation">
					<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
	<h3 id="p-views-label">Views</h3>
	<ul>
					<li id="ca-view" class="selected"><span><a href="/wiki/Novartis" >Read</a></span></li>
					<li id="ca-edit"><span><a href="/w/index.php?title=Novartis&amp;action=edit"  title="You can edit this page. &#10;Please review your changes before saving. [e]" accesskey="e">Edit</a></span></li>
					<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Novartis&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
			</ul>
</div>
<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
	<h3 id="p-cactions-label"><span>Actions</span><a href="#"></a></h3>
	<div class="menu">
		<ul>
					</ul>
	</div>
</div>
<div id="p-search" role="search">
	<h3><label for="searchInput">Search</label></h3>
	<form action="/w/index.php" id="searchform">
					<div id="simpleSearch">
					<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />		</div>
	</form>
</div>
				</div>
			</div>
			<div id="mw-panel">
					<div id="p-logo" role="banner"><a style="background-image: url(//upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
				<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
	<h3 id='p-navigation-label'>Navigation</h3>
	<div class="body">
		<ul>
			<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
			<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
			<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li>
			<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
			<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			<li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li>
			<li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikimedia Shop</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
	<h3 id='p-interaction-label'>Interaction</h3>
	<div class="body">
		<ul>
			<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
			<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
			<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
			<li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
	<h3 id='p-tb-label'>Tools</h3>
	<div class="body">
		<ul>
			<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Novartis" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
			<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Novartis" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
			<li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li>
			<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li>
			<li id="t-permalink"><a href="/w/index.php?title=Novartis&amp;oldid=602624408" title="Permanent link to this revision of the page">Permanent link</a></li>
			<li id="t-info"><a href="/w/index.php?title=Novartis&amp;action=info">Page information</a></li>
			<li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q507154" title="Link to connected data repository item [g]" accesskey="g">Data item</a></li>
<li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Novartis&amp;id=602624408" title="Information on how to cite this page">Cite this page</a></li>		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
	<h3 id='p-coll-print_export-label'>Print/export</h3>
	<div class="body">
		<ul>
			<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Novartis">Create a book</a></li>
			<li id="coll-download-as-rl"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Novartis&amp;oldid=602624408&amp;writer=rl">Download as PDF</a></li>
			<li id="t-print"><a href="/w/index.php?title=Novartis&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
	<h3 id='p-lang-label'>Languages</h3>
	<div class="body">
		<ul>
			<li class="interlanguage-link interwiki-als"><a href="//als.wikipedia.org/wiki/Novartis" title="Novartis – Alemannisch" lang="als" hreflang="als">Alemannisch</a></li>
			<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D9%86%D9%88%D9%81%D8%A7%D8%B1%D8%AA%D8%B3" title="نوفارتس – Arabic" lang="ar" hreflang="ar">العربية</a></li>
			<li class="interlanguage-link interwiki-bg"><a href="//bg.wikipedia.org/wiki/%D0%9D%D0%BE%D0%B2%D0%B0%D1%80%D1%82%D0%B8%D1%81" title="Новартис – Bulgarian" lang="bg" hreflang="bg">Български</a></li>
			<li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/Novartis" title="Novartis – Catalan" lang="ca" hreflang="ca">Català</a></li>
			<li class="interlanguage-link interwiki-cs"><a href="//cs.wikipedia.org/wiki/Novartis" title="Novartis – Czech" lang="cs" hreflang="cs">Čeština</a></li>
			<li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Novartis" title="Novartis – German" lang="de" hreflang="de">Deutsch</a></li>
			<li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/Novartis" title="Novartis – Spanish" lang="es" hreflang="es">Español</a></li>
			<li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D9%86%D9%88%D8%A7%D8%B1%D8%AA%DB%8C%D8%B3" title="نوارتیس – Persian" lang="fa" hreflang="fa">فارسی</a></li>
			<li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Novartis" title="Novartis – French" lang="fr" hreflang="fr">Français</a></li>
			<li class="interlanguage-link interwiki-ko"><a href="//ko.wikipedia.org/wiki/%EB%85%B8%EB%B0%94%ED%8B%B0%EC%8A%A4" title="노바티스 – Korean" lang="ko" hreflang="ko">한국어</a></li>
			<li class="interlanguage-link interwiki-id"><a href="//id.wikipedia.org/wiki/Novartis" title="Novartis – Indonesian" lang="id" hreflang="id">Bahasa Indonesia</a></li>
			<li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Novartis" title="Novartis – Italian" lang="it" hreflang="it">Italiano</a></li>
			<li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%A0%D7%95%D7%91%D7%A8%D7%98%D7%99%D7%A1" title="נוברטיס – Hebrew" lang="he" hreflang="he">עברית</a></li>
			<li class="interlanguage-link interwiki-hu"><a href="//hu.wikipedia.org/wiki/Novartis" title="Novartis – Hungarian" lang="hu" hreflang="hu">Magyar</a></li>
			<li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Novartis" title="Novartis – Dutch" lang="nl" hreflang="nl">Nederlands</a></li>
			<li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E3%83%8E%E3%83%90%E3%83%AB%E3%83%86%E3%82%A3%E3%82%B9" title="ノバルティス – Japanese" lang="ja" hreflang="ja">日本語</a></li>
			<li class="interlanguage-link interwiki-no"><a href="//no.wikipedia.org/wiki/Novartis" title="Novartis – Norwegian (bokmål)" lang="no" hreflang="no">Norsk bokmål</a></li>
			<li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Novartis" title="Novartis – Polish" lang="pl" hreflang="pl">Polski</a></li>
			<li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/Novartis" title="Novartis – Portuguese" lang="pt" hreflang="pt">Português</a></li>
			<li class="interlanguage-link interwiki-ro"><a href="//ro.wikipedia.org/wiki/Novartis" title="Novartis – Romanian" lang="ro" hreflang="ro">Română</a></li>
			<li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/Novartis" title="Novartis – Russian" lang="ru" hreflang="ru">Русский</a></li>
			<li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Novartis" title="Novartis – Simple English" lang="simple" hreflang="simple">Simple English</a></li>
			<li class="interlanguage-link interwiki-sr"><a href="//sr.wikipedia.org/wiki/%D0%9D%D0%BE%D0%B2%D0%B0%D1%80%D1%82%D0%B8%D1%81" title="Новартис – Serbian" lang="sr" hreflang="sr">Српски / srpski</a></li>
			<li class="interlanguage-link interwiki-sh"><a href="//sh.wikipedia.org/wiki/Novartis" title="Novartis – Serbo-Croatian" lang="sh" hreflang="sh">Srpskohrvatski / српскохрватски</a></li>
			<li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Novartis" title="Novartis – Finnish" lang="fi" hreflang="fi">Suomi</a></li>
			<li class="interlanguage-link interwiki-ta"><a href="//ta.wikipedia.org/wiki/%E0%AE%A8%E0%AF%8B%E0%AE%B5%E0%AE%BE%E0%AE%B0%E0%AF%8D%E0%AE%9F%E0%AF%8D%E0%AE%9F%E0%AF%80%E0%AE%9A%E0%AF%81" title="நோவார்ட்டீசு – Tamil" lang="ta" hreflang="ta">தமிழ்</a></li>
			<li class="interlanguage-link interwiki-th"><a href="//th.wikipedia.org/wiki/%E0%B9%82%E0%B8%99%E0%B8%A7%E0%B8%B2%E0%B8%A3%E0%B9%8C%E0%B8%95%E0%B8%B4%E0%B8%AA" title="โนวาร์ติส – Thai" lang="th" hreflang="th">ไทย</a></li>
			<li class="interlanguage-link interwiki-tr"><a href="//tr.wikipedia.org/wiki/Novartis" title="Novartis – Turkish" lang="tr" hreflang="tr">Türkçe</a></li>
			<li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E8%AF%BA%E5%8D%8E%E5%85%AC%E5%8F%B8" title="诺华公司 – Chinese" lang="zh" hreflang="zh">中文</a></li>
			<li class="uls-p-lang-dummy"><a href="#"></a></li>
			<li class="wbc-editpage"><a href="//www.wikidata.org/wiki/Q507154#sitelinks-wikipedia" title="Edit interlanguage links">Edit links</a></li>
		</ul>
	</div>
</div>
			</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 3 April 2014 at 19:40.<br /></li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a class="external" href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/wiki/Novartis" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
					<li id="footer-copyrightico">
						<a href="//wikimediafoundation.org/"><img src="//bits.wikimedia.org/images/wikimedia-button.png" width="88" height="31" alt="Wikimedia Foundation"/></a>
					</li>
					<li id="footer-poweredbyico">
						<a href="//www.mediawiki.org/"><img src="//bits.wikimedia.org/static-1.23wmf20/skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" width="88" height="31" /></a>
					</li>
				</ul>
						<div style="clear:both"></div>
		</div>
		<script>/*<![CDATA[*/window.jQuery && jQuery.ready();/*]]>*/</script><script>if(window.mw){
mw.loader.state({"site":"loading","user":"ready","user.groups":"ready"});
}</script>
<script>if(window.mw){
mw.loader.load(["ext.cite","mobile.desktop","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.DRN-wizard","ext.gadget.charinsert","mw.MwEmbedSupport.style","mmv.bootstrap.autostart","ext.eventLogging.subscriber","ext.navigationTiming","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage","skins.vector.collapsibleNav"],null,true);
}</script>
<script src="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=scripts&amp;skin=vector&amp;*"></script>
<!-- Served by mw1216 in 2.815 secs. -->
	</body>
</html>
